Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  02-APR-2019A Randomized Double Blind Clinical Trial to Evaluate the Effects of
MK-[ADDRESS_1275464]: MK-7264  1
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD) .
Protocol Title: A Randomized Double Blind Clinical Trial to Evaluate the Effects of MK -
7264 in Participants with Obstructive Sleep Apnea
Protocol Number: 039-02
Compound Number: MK-7264
Sponsor Name:
[CONTACT_19519] & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey , [ZIP_CODE] -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND 141,[ADDRESS_1275465] 2018- 004099- 37
Approval Date: [ADDRESS_1275466]: MK-7264  2
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
[CONTACT_1641]:Date 
  056LPF 
  05FQVP
PRODUCT: MK-7264  3
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275467]: MK-7264  4
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: 02
Overall Rationale for the Amendments:
Following publication of Protocol [ADDRESS_1275468] of prohibited medications.
Summary of Changes Table:
Section # and Name [CONTACT_908524].
Section 1.3: Schedule of Activities (SoA) Added a line for blood and urine 
collections for in clinic PSG daysThe revisions reflect clarification of the 
SoA.
Section 1.3: Schedule of Activities (SoA) Added additional flexibility  for timing of 
admission arrival and procedures.The revision is to accommodate patient 
and site schedules.
Section 1.3: Schedule of Activities (SoA) Added that patient a llocation number will 
be added to the Participant I D Card at 
randomization .The revisions reflect clarification of the 
SoA.
Section 2.3: Pharmaceutical and 
Therapeutic BackgroundAdded updated in vitro MK-[ADDRESS_1275469]: MK-7264  5
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Section # and Name [CONTACT_9353] 5.2: Exclusion Criteria Added pi[INVESTIGATOR_908479].The revisions reflect the updated 
prohibited medications list based on 
newly  avai lable in vitro transporter 
inhibition data.
Section 5.2: Exclusion Criteria Added history  of allergy  to sulfonamide -
containing drugs to the exclusion criteri a.   The revision reflects theupdate dallergy  
exclusion criterion .  
Section 5.2: Exclusion Criteria Updated eGFR criterion The revisions reflect the updated eGFR 
exclusion criterion.
Section [IP_ADDRESS]: Diet Restrictions Clarified diet restrictions for assessment 
visits.The revisions reflect the clarification of 
diet r estrictions . 
  056LPF 
  05FQVP
PRODUCT: MK-7264  6
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Table of Contents
DOCUMENT HISTORY ........................................................................................................3
PROTOCOL AMENDMENT S UMMARY OF CHANGES ................................
............... 4
1 PROTOCOL SUMMARY ............................................................................................ 13
1.1 Synopsis ................................................................................................................. 13
1.2 Schema .................................................................................................................. 16
1.3 Schedule of Activities (SoA) ................................................................................ 17
2 INTRODUCTION .......................................................................................................... 23
2.1 Study Rationale ....................................................................................................24
2.2 Background .......................................................................................................... 25
2.3 Pharmaceutical and Therapeutic Background ................................................. 25
2.4 Preclinical and Clinical Studies .......................................................................... 25
2.5 Ongoing Clinical Studies ..................................................................................... 27
2.6 Benefit/Risk Assessment ...................................................................................... 27
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 27
4 STUDY DESIGN ............................................................................................................ 30
4.1 Overall Design ......................................................................................................30
4.2 Scientific Rationale for Study Design ................................................................ .31
4.2.1 Rationale for Endpoints ............................................................................... 32
[IP_ADDRESS] Efficacy  and Safet y Endpoints ........................................................... 32
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 33
[IP_ADDRESS] Pharmacod ynamic Endpoints ............................................................. 33
[IP_ADDRESS] Planned Exploratory  Biomarker Research ......................................... 34
[IP_ADDRESS].1 Planned Genetic Anal ysis........................................................ 34
[IP_ADDRESS] Future Biomedical Research .............................................................. 34
4.2.2 Rationale for the Use of Placebo ................................................................ .34
4.3 Justification for Dose ........................................................................................... 35
4.4 Beginning and End of Study Definition ............................................................. 35
4.4.1 Clinical Criteria for Early Study Termination ............................................. 36
5 STUDY POPULATION ................................................................................................ 36
5.1 Inclusion Criteria ................................................................................................ .36
5.2 Exclusion Criteria ................................................................................................ 38
5.3 Lifestyle Considerations ...................................................................................... 44
5.3.1 Meals and Dietary Restrictions ....................................................................44
[IP_ADDRESS] Diet Restrictions................................................................................. [ADDRESS_1275470]: MK-7264  7
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
[IP_ADDRESS] Caffeine Restrictions .......................................................................... 44
[IP_ADDRESS] Alcohol Restrictions ........................................................................... 44
5.3.3 Tobacco Restrictions .................................................................................... 44
5.3.4 Activity  Restrictions .................................................................................... 45
5.4 Screen Failures .....................................................................................................45
5.5 Participant Replacement Strategy ......................................................................45
6 STUDY INTERVENTION ............................................................................................ 45
6.1 Study Intervention(s) Administered ...................................................................45
6.2 Preparation/Handling/Storage/Accountability ................................................. 47
6.2.1 Dose Preparation .......................................................................................... 47
6.2.2 Handling, Storage, and Accountability ........................................................ 47
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. [ADDRESS_1275471] to Follow -up................................................................................................ .51
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 51
8.1 Administrative and General Procedures ........................................................... 52
8.1.1 Informed Consent ......................................................................................... 52
[IP_ADDRESS] General Informed Consent ................................................................ .52
[IP_ADDRESS] Consent and Collection of Spe cimens for Future Biomedical 
Research ............................................................................................. 53
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_1275472] .....................................................................53
8.1.4 Medical History ........................................................................................... 53
8.1.5 Prior and Concomitant Medications Review ............................................... 53
[IP_ADDRESS] Prior Medications ............................................................................... [ADDRESS_1275473]: MK-7264  8
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
[IP_ADDRESS] Concomitant Medications ..................................................................54
8.1.6 Assignment of Screening Number ............................................................... 54
8.1.7 Assignment of Treatment/Randomization Number .....................................54
8.1.8 Study  Intervention Administration .............................................................. 54
[IP_ADDRESS] Timing of Dose Administration ......................................................... 55
8.1.9 Discontinuation and Withdrawal ................................................................ .55
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 55
8.1.10 Participant Blinding/Unblinding ..................................................................56
8.1.11 Domiciling ...................................................................................................56
8.1.12 Calibration of Equipment ............................................................................. 56
8.2 Efficacy Assessments ........................................................................................... 57
8.2.1 Polysomnography ........................................................................................ 57
8.2.2 Emerald Device Sleep Data Capture ............................................................ 57
8.2.3 Morning Sleep Questionnaire (MSQ).......................................................... 58
8.2.4 Epworth Sleepi[INVESTIGATOR_7110] (ESS) ..................................................................58
8.2.5 Functional Outcomes of Sleep Questionnaire (FOSQ) ................................ 58
8.3 Safety Assessments ............................................................................................... 58
8.4 Physical Examinations ......................................................................................... 58
8.4.1 Complete Phy sical Examinations ................................................................ 58
8.4.2 Focused Ph ysical Examinations ...................................................................59
8.4.3 Calculate Bod y Mass Index .........................................................................59
8.4.4 Vital Signs....................................................................................................59
8.4.5 Electrocardiograms ...................................................................................... 59
8.4.6 Renal and Urological Safety  Procedures ..................................................... 60
8.4.7 Pregnancy  Testing ........................................................................................ 60
8.4.8 Exploratory  Blood and Urine Clinical Biomarkers .....................................60
8.5 Clinical Safety Laboratory Assessments ............................................................ 60
8.6 Other Assessments ............................................................................................... 61
8.6.1 Study  Intervention Diary .............................................................................. 61
8.7 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... [ADDRESS_1275474]: MK-7264  9
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
8.7.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_1275475] (ECI s)................................................................ 64
8.8 Treatment of Overdose ........................................................................................ 65
8.9 Pharmacokinetics................................................................................................ .65
8.9.1 Blood Collection for Plasma MK- 7264 ....................................................... 65
8.10 Planned Genetic Analysis Sample Collection .................................................... 65
8.11 Future Biomedical Research Sample Collection ............................................... 66
8.12 Visit Requirements ............................................................................................... 66
8.12.1 Screening......................................................................................................66
8.12.2 Treatment Period .......................................................................................... 66
8.12.3 Discontinued Participants Continuing to be Monitored in the Study .......... 67
8.12.4 Poststudy ......................................................................................................67
8.12.5 Critical Procedures Based on Study  Objectives: Timing of Procedure .......67
8.12.6 Study  Design/Dosing/Procedures Modifications Permitted Within 
Protocol Parameters ..................................................................................... 68
9 STATISTICAL ANALYSIS PLAN ............................................................................. 69
9.1 Statistical Analysis Plan Summary.....................................................................69
9.2 Responsibility for Analyses ................................................................................. 69
9.3 Hypotheses/Estimation ........................................................................................ 70
9.4 Analysis Endpoints ............................................................................................... 71
9.5 Analysis Populations ............................................................................................ 72
9.6 Statistical Methods ............................................................................................... 72
9.7 Interim Analyses ..................................................................................................74
9.8 Multiplicity ........................................................................................................... 74
9.9 Sample Size and Power Calculations ................................................................ .74
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS .....................................................................................................76
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........[ADDRESS_1275476] for Clinical Trials ............................................................. 76
10.1.2 Financial Disclosure ..................................................................................... 78
10.1.3 Data Protection ............................................................................................. 78
[IP_ADDRESS] Confidentiality  of Data ......................................................................79
[IP_ADDRESS] Confidentiality  of Participant Records ............................................... 79
[IP_ADDRESS] Confidentiality  of IRB/IEC I nformation ............................................ [ADDRESS_1275477]: MK-7264  10
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
10.1.7 Data Qualit y Assurance ............................................................................... 81
10.1.8 Source Documents ....................................................................................... 81
10.1.9 Study  and Site Closure ................................................................................. 82
10.2 Appendix 2: Clinical Labor atory Tests .............................................................. 83
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 84
10.3.1 Definition of AE .......................................................................................... 84
10.3.2 Definition of SAE ........................................................................................ 85
10.3.3 Additional Events Reported in the Same Manner as SAE ........................... 86
10.3.4 Recording AE and SAE ............................................................................... 86
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................87
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation ....................................89
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing ........................ 90
10.5.1 Definitions....................................................................................................90
10.5.2 Contraception Requirements ........................................................................91
10.5.3 Pregnancy  Testing ........................................................................................ 92
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedic al Research ............................................................................................ 93
10.7 Appendix 7: Country -specific Requirements .................................................... 98
10.8 Appendix 8: Blood Volume Table ......................................................................99
10.9 Appendix 9: 12- Lead Electrocardiogram Abnormality Criteria .................. 100
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values ...102
10.11 Appendix 11: Abbreviations ............................................................................. [ADDRESS_1275478]: MK-7264  11
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275479]: MK-7264  12
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275480]: MK-7264  13
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
1 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Randomized Double Blind Clinical Tria l to Evaluate the Effects of 
MK-7264 in Participants with Obstructive Sleep Apnea
Short Title: MK-7264 Trial in Participants with Obstructive Sleep Apnea
Acronym:
Hypotheses, Objectives ,and Endpoints :
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
Male/Female participants with moderate to severe obstructive sleep apnea between the ages 
of 18and 75 years(inclusive) will be enrolled in this trial.
Overall Desig n:
Study  Phase Phase 1
Primary  Purpose Treatment
Indication Treatment of Obstructive Sleep Apnea
Population Male and female adults with moderate to severe 
obstructive sleep apnea (OSA) who do not use positive 
airway  pressure (PAP) th erapy.
Study  Type Interventional
Intervention Model Cross -over
This is a multi- sitestudy in the US and Europe .
Type of Control Placebo
Study  Blinding Double -blind
Masking Investigator
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately [ADDRESS_1275481] participant’s last 
study -related telephone call or visit. 
  056LPF 
  05FQVP
PRODUCT: MK-7264  14
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Number of Participant s:
Approximately  16participants will be allocated/randomized .
Intervention Groups and Du ration :
Intervention 
Group sIntervention 
Group Name [CONTACT_908525]-7264 180 mgQHS x 7
daysOral Period 1 or 2
Placebo 0 mgQHS x 7
daysOral Period 1 or 2
Abbreviations:
QHS: daily at bedtime
Total 
NumberThere will be a total of [ADDRESS_1275482] 8 participants.
Treatment 
SequencePeriod 1 Period 2
1
(n=8)Placebo MK-7264 180 mg
2
(n=8)MK-7264 180 mg Placebo
Duration of 
ParticipationEach participant will participate in the study  for approximately  10weeks
from the time the participant signs the Informed Consent F orm (ICF) 
through the final contact. 
  056LPF 
  05FQVP
PRODUCT: MK-7264  15
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Study Governance Committees:
Steering Committee No
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 10.1.
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this doc ument can be found in Appendix 10.11. 
  056LPF 
  05FQVP
PRODUCT: MK-7264  16
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275483]: MK-7264  17
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
1.3 Schedule of Activities (SoA)
Study Period Screening Periods [ADDRESS_1275484]-
study 
VisitProcedures scheduled for
Randomization occur in Period 1 
only
Study Days Day -36 Day -22 Day -15 Day -1 Day -1 Days 1 -6 Day 7 Days 8 -13Day 21
(After 
Period 2
only)
Visit Window (days) +13 +/- 3 +/- 5 + 3 + 2 +/- 2Visit Windows denote flexibility of 
certain scheduled Visits. “+” means 
Visit can be delayed by X days; “ -“ 
means Visit can be scheduled ahead 
by X days.
Adm inistrative Procedures
Assignment of Screening 
NumberX
Informed Consent X
Informed Consent for Future 
Biomedical ResearchX
Participant I dentification 
CardX XAllocation number will be added to 
the Participant I D Card at 
Randomization
Inclusion/Exclusion Criteria X X X X
Medical History X
Prior/Concomitant 
Medication ReviewX ----------------------------------------------------------------------------------------------------------------------------- --------- X
Assignment of 
Treatment/Randomization 
NumberXSite should refer to Study 
Operations Manual for details on 
participant assignment . All safety 
procedures should be completed 
prior to treatment assignment.
Dosing and Other Related Procedures
MK-7264/Placebo and Study 
Intervention Diary 
Dispensing  X
MK-7264/Placebo 
Administration (at home )XParticipants should take the 
assigned treatment as instructed by 
[CONTACT_779] 
  056LPF 
  05FQVP
PRODUCT: MK-7264  18
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275485]-
study 
VisitProcedures scheduled for
Randomization occur in Period 1 
only
Study Days Day -36 Day -22 Day -15 Day -1 Day -1 Days 1 -6 Day 7 Days 8 -13Day 21
(After 
Period 2
only)
Visit Window (days) +13 +/- 3 +/- 5 + 3 + 2 +/- 2Visit Windows denote flexibility of 
certain scheduled Visits. “+” means 
Visit can be delayed by X days; “ -“ 
means Visit can be scheduled ahead 
by X days.
Study I ntervention Reminder 
Contact[CONTACT_908502] -administer study 
intervention.
Study I ntervention Diary (at 
home )XParticipants should complete the 
study intervention diary after each 
dosing at home
MK-7264/Placebo 
Administration (in clinic )X
Collection of MK -7264 / 
Placebo bottles and Study 
Intervention Diary as 
applicableX
Standard Meals  X X X X
Efficacy/Pharmacodynamic Procedures
Hyperoxia Challenge X
Polysomnography (PSG) X X X XSee sub -flow chart below for 
detailed timing of procedures on 
PSG/in -clinic days
Epworth Sleepi[INVESTIGATOR_7110] 
(ESS)X X X
Morning Sleep Questionnaire 
(MSQ ) DispensingX
Morning Sleep Questionnaire 
(MSQ)X X X XMSQ should be completed within 
15 minutes of rising as instructed by 
[CONTACT_908503] (FOSQ)X X X 
  056LPF 
  05FQVP
PRODUCT: MK-7264  19
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275486]-
study 
VisitProcedures scheduled for
Randomization occur in Period 1 
only
Study Days Day -36 Day -22 Day -15 Day -1 Day -1 Days 1 -6 Day 7 Days 8 -13Day 21
(After 
Period 2
only)
Visit Window (days) +13 +/- 3 +/- 5 + 3 + 2 +/- 2Visit Windows denote flexibility of 
certain scheduled Visits. “+” means 
Visit can be delayed by X days; “ -“ 
means Visit can be scheduled ahead 
by X days.
Emerald Device Sleep Data 
Capture X X X XEmerald device will be included for 
US sites only as described in 
Section 8.2.2.
Safety Procedures
Full Physical Examination X X
Focused Physical Exam X X XaX X
Height X
Weight X
Vital Signs
(BP/HR/RR/Body 
Temperature)X X X X XSpO2 will be assessed at Screening 
Visit 1 for I/E Criteria
12-lead ECG X X X
Urine or Serum Pregnancy 
Test (WOCBP only)X XaX X
HIV, Hepatitis B and C 
Screen (per site SOP)X
Urine Drug Screen (UDS) 
(per site SOP)X XaX
Laboratory Safety Tests 
(Chemistry, Hematology, 
Urinalysis (with microscopy))X XaX X X
AE/SAE review X ----------------------------------------------------------------------------------------------------------------------------- --------- X 
  056LPF 
  05FQVP
PRODUCT: MK-7264  20
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275487]-
study 
VisitProcedures scheduled for
Randomization occur in Period 1 
only
Study Days Day -36 Day -22 Day -15 Day -1 Day -1 Days 1 -6 Day 7 Days 8 -13Day 21
(After 
Period 2
only)
Visit Window (days) +13 +/- 3 +/- 5 + 3 + 2 +/- 2Visit Windows denote flexibility of 
certain scheduled Visits. “+” means 
Visit can be delayed by X days; “ -“ 
means Visit can be scheduled ahead 
by X days.
Pharmacok inetics
Blood for Plasma MK -7264 XBlood for MK -7264 PK will be 
collected at the following time 
points: Day 7 of each Period: 
predose, [ADDRESS_1275488] dose, and 
lights on.
Biomark ers
Blood (DNA) for Planned 
Genetic Analysisb, c XCollect from randomized 
participants at Period 1 only.
Blood (serum and plasma) for 
Clinical Biomarkersc X X
Urine for Clinical 
Biomarkersc X X
aEvents that are marked for both Randomization (Day -1) and Period 1 Baseline (Day -1) should only be performed once. They should not be duplicated.
bThis sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. This s ample will not be collected at that 
site if there is either a local law or regulation prohibiting collection, or if the I RB/I EC do es not approve the collection of the sample for these purposes. If the 
sample is collected, leftover extracted DNA will be stored for future biomedical research if the participant signs the future biomedical research consent. I f the 
planned genetic analy ses are not approved, but future biomedical research is approved, and consent is given, this sample will be collected for the purpose of future 
biomedical research
cLeftover from these samples are subject to FBR as described in Section 8.11.
Detailed Sc hedule of Activities for I n Clinic PSG Day s
Note : the purpose of the table below is to provide details on the timing in relation of the procedures on PSG day s. Not every  single 
procedure is schedule dfor each PSG day . Please refer to the Schedule of Activi ties above to see which procedures are applicable 
during each visit. 
  056LPF 
  05FQVP
PRODUCT: MK-7264  21
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Arrival
(within
-6 hours)Within -4 
hours-1.5
hour-1.0hour‘Lights 
Off’
0 hour‘Lights On’
[ADDRESS_1275489] 
‘Lights 
On’Discharge
Randomization Procedures ( as 
described in SoA above, Period 1 
Baseline only)X
Collection of MK-7264/Placebo 
Bottles , Study Intervention Diary, and 
MSQ (only on assessment days)X
Safety Procedures (Focused Physical 
Examd, Vital Signs)X
Vital Signs X X
Blood Collection for MK -7264 PKa
(only on assessment days)X X Xb
MK-7264/Placebo Administration
(only on assessment days)X
Standard Meal X X
PSG Set -Up X---------------------- -------- X
PSG including Finger Pulse Oximetry 
(SaO 2monitoring)X---------------------- X
Hyperoxia Challenge (Screening Visit 
3only)X---------------------- X
Emerald Device Sleep Data Capture X---------------------- X
Laboratory Safety Tests (Chemistry, 
Hematology, Urinalysis)Xb
Clinical Biomarker Sample Collection
(urine & blood)Xb
Morning Sleep Questionnaire (MSQ)c X
Epworth Sleepi[INVESTIGATOR_7110] (ESS) X
Functional Outcomes of Sleep 
Questionnaire ( FOSQ )X
Dispense study medication / Drug 
Diary, Morning Sleep Questionnaire 
(MSQ)X 
  056LPF 
  05FQVP
PRODUCT: MK-7264  22
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Arrival
(within
-6 hours)Within -4 
hours-1.5
hour-1.0hour‘Lights 
Off’
0 hour‘Lights On’
[ADDRESS_1275490] 
‘Lights 
On’Discharge
aBlood for MK -7264 PK will be collected at the following time points: Days 7 of each Period : predose, 30 minutes postdose , and lights on.
bBlood and urine collection for biomarker /PKsamples collected at “lights -on” should be drawn at the same time. PGA sample collected at Baseline, Period 1 may also be 
collected at this time.
c MSQ should be completed within 15 minutes of rising as instructed by [CONTACT_779].
d Physical exam may be performed within 1 hour of “Lights -On”. 
  056LPF 
  05FQVP
PRODUCT: MK-7264  23
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
2 INTRODUCTION
Approximately  twent y six percent of American adults suffer from obstructive sleep apnea 
(OSA )[Peppard, P. E., et al 2013] .Patients with OSA are at increased risk for multiple co -
morbidities, including ,but not limited ,tohypertension, diabetes, stroke, depression, and 
early mortalit y [Young, T., et al 2009] [Pagel, J. F. 2007] [Hale, C. S. 2005] [Parish, J. M., et 
al 2007] .This burden is amplified by  [CONTACT_908504], bod y mass index (BMI)
,and gender matched controls 
[Pagel, J. F. 2007] .The first -line treatment for OSA is a positive airway  pressure (PAP)
device , which reduces but does not eliminate the co- morbidities associated with OSA [Pagel, 
J. F. 2007] .Unfortunately, PAP is cumbersome and poorly tolerated, leading to low long -
term adherence rates of approximately  50% [Weaver, T. E., et al 1997] [Means, M. K., et al 
2004] [Rotenberg, B. W., et al 2016] [Rotenberg, B. W., et al 2016]. Thus, a noral 
pharmacological treatment that can either increase the efficacy  of PAP or supplant the need 
for PAP completely  would be a significant medical advance for OSA patients.
Pathophysiology of OSA : OSA is a heterogen eous syndrome that results from obstructive
(mechanical/anatomic) , central (absence of inspi[INVESTIGATOR_77583]) or mixed (obstructive plus 
central) features. In all cases of OSA, there is d ysregulation of respi[INVESTIGATOR_908480], which can lead to airway s that either have ineffective dilation or 
prema turely collapse [Dempsey , J. A., et al 2014] (Figure 2).Additional factors that 
contribute to OSA are low arousal threshold, prolonged circulation time and High Loop Gain 
(HLG) . HLG is an engineering term applied in respi[INVESTIGATOR_908481] a ventilatory  response evo ked b y a ventilatory  disturbance 
[Dempsey , J. A., et al 2014] ; HLG describes a situation in which the ventilatory  response is 
inappropriately high relative to the ventilatory  disturbance. The exaggerated response to the 
levels of O2 and CO2 by  [CONTACT_908505]  (e.g. from poor 
circulation or autonomic dy sregulation) can lead to high ventilatory  drive in patients with 
HLG such that , following even a brief, mild apneic event, the airways open and 
hypervent ilation occurs. This in turn restarts the cycle of hy pocapnia and a paradoxical apnea 
or hy popnea.  In patients with HL G, supplemental oxy gen increases SaO2 and effectivel y 
reduces the disconnect between the perception of hy poxia by  [CONTACT_908506] .  In a subgroup of patients with oxygen responsive or 
chemoreflex -dependent OSA (high loop gain and milder phary ngeal collapsibility ), lowering 
loop gain (with supplemental O 2) greatly im proves OSA severit y; approximately  25% of 
patients lowered Apnea -Hypopnea Index ( AHI)by >50% and 1 in 6 patients had no OSA on 
treatment [Sands, S. A., et al 2018] . HLGis found in approximately 33% of patients with 
OSA , including those with mechanical obstruction, and contributes to the pathophy siology
by [CONTACT_908507]-and hy poventilation [Dempsey , J. A., et al 
2014] .  
  056LPF 
  05FQVP
PRODUCT: MK-7264  24
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Figure 2Putative mechanism of contribution of carotid body activation and HLG to OSA
This response results in respi[INVESTIGATOR_908482]/or apnea 
during sleep [Dempsey , J. A., et al 2014] [Younes, M. 2014] (Figure 2). Antagonism of the 
carotid bod y afferents could normaliz e HLG and treat OSA [Paton, J. F. R., et al 2013] .
2.[ADDRESS_1275491] been performed 
using the respi[INVESTIGATOR_908483], a carbonic anh ydrase inhibitor [Edwards, B. 
A., et al 2012] [Edwards, B. A., et al 2012] [Nussbaumer
-Ochsner, Y., et al 2012] . 
Acetazolamide produces a metabolic acidosis , which increase sthe baseline ventilatory  drive
in patients with OSA. This response can lower loop gain and the AHI [Edwards, B. A., et al 
2012] . However, chronic acetazolamide treatment is not a viable long -term therapy  as it leads 
to harmful metabolic changes. These studies support the hypothesis that lowering loop gain 
pharmacologically  can have a beneficial impact on patients with OSA.
Thistrial is a Ph ase 1bproof of concept ( PoC) placebo -controlled, double -blind, crossover 
study  thatwill test the hypothesis that MK-7264 will reduce OSA severity (AHI) in 
chemoreflex -dependent patients with OSA. A positive outcome of this study would support
further stud y of agents, such as MK -7264, that normalize carotid body inputs in patients with 
OSA .
 
  056LPF 
  05FQVP
PRODUCT: MK-7264  25
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
2.2 Background
Refer to the Investigator’s Brochure (IB )for detailed background information on MK- 7264.
2.[ADDRESS_1275492] .P2X3 is a ligand -gated ion channel that is primarily  
expressed on afferent sensory  c-fibers and that opens in response to extracellular ATP 
released by  [CONTACT_908508] a neurotransmitter from 
presynaptic vesicles. P2X3 receptors can be homotrimer (containing onl y P2X3) or 
heterotrimer ( containing P2X2/3). MK -[ADDRESS_1275493] and is a 
potent inhibitor with an IC50 of 20- 70 nM for P2X3 and 150 -300 nM for P2X2/3, with at 
least 100 -fold selectivity  over other P2X channels [North, R. A. 2004] .
In vitro s tudies assessing the potential for MK -7264 to inhibit the human transporters 
Organic Anion Transporting Polypeptide 1B1 (OATP1B1), OATP1B3, Organic Cation 
Transporter 1 (OCT1), OCT2, Organic Anion Transporter 1 (OAT1), OAT3, Multidrug and 
Toxin Extrusion Protein 1 (MATE1), MATE2K, Breast Cancer Resistance Protein (BCRP), 
and Bil e Salt Extrusion Pump (BSEP) were performed . 
No clinica lly meaningful inhibition of OCT2, OAT1, OAT3, BCRP and BSEP was 
measured. At an in vitro concentration approximately  equivalent to that achieved with a 
180 mg QD dose , MK -7264 has the potential to inhibit OATP1B1 -and OATP1B3 -mediated 
hepatic uptake, wi th in vitro I C50 values of 35 µM and 97 µM, and calculated R -values (the 
predicted ratio of the victim drug’s AUC in the presence and absence of perpetrator drug) of 
1.5 and 1.2 for OATP1B1 and - 1B3, respectivel y. MK -7264 also has the potential to inhibit 
OCT1- mediated hepatic uptake (IC50=17.2 µM, R=1.9) ,MATE1 (IC50=34.7 µM; 
Cmax,u/I C50=0.07) ,and MATE2K (IC50=31.5 µM; Cmax,u/I C50=0.08) mediated api[INVESTIGATOR_908484]. Based on these observations, the likelihood of a 
clinically  signi ficant DDI with substrates of OATP1B1, OATP1B3, OCT1, MATE1 and 
MATE2K is considered to be low, but cannot be excluded.
2.4 Preclinical and Clinical Studies
Aberrant sy mpathetic nervous sy stem excitation is linked to the pathology  and morbidity  of a 
variet y ofcardiorespi[INVESTIGATOR_146456] ,and one factor contributing to s ympathoexcitation is 
OSA [Tay lor, K. S., et al 2018] . Additionally , OSA can exacerbate ventilatory  instability
[Younes, M. 2014] . It has been shown that supplemental oxy gen can treat ventilatory  
instability  by [CONTACT_908509], resulting in a reduction of the 
AHI [Edwards, B. A., et al 2014] . In dogs, carotid body  denervation reduced apneas and 
periodic breathing resulting from transient h yperventilations and hypercapnia [Nakay ama, 
H., et al 2003]
. An animal model of heightened s ympathetic activity, the spontaneously 
hypertensive rat (SHR), was used to demonstrate the role of P2X3 in peripheral 
chemoreceptors in the carotid body  [Paton, J. F. R., et al 2013] [Pi[INVESTIGATOR_908485], W., et al 2016] . In 
this series of studies, electrophysiological recordings from the carotid sinus nerve innervating 
the carotid bod y demonstrated the exaggerated response to hypoxia in SHRs relative to  
  056LPF 
  05FQVP
PRODUCT: MK-7264  26
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Wistar rat controls. This hyperreflexic response to hypoxia in the SHR was restored to the 
normal magnitude of response seen in the Wistar through pharmacological blockade with a 
selective P2X3/P2X2/[ADDRESS_1275494] (‘AF -353’, a close analogue to MK -7264). Addit ionally , 
treatment with MK -7264 significantl y reduced renal sympathetic nerve activity [Pi[INVESTIGATOR_908485], W., 
et al 2016] .
The apneas of prematurity that occur in newborn rats is a model for OSA [Bairam, A., et al 
2013] . In this model, blockade of P2X3 and P2X2/3 by  ‘AF -454’ (another close analogue of 
MK-7264) had no effect on breathing under normoxic conditions but dramatically reduced 
hypoxia -induced hyperventilation and sign ificantly  reduced the frequency  of apneas as 
measured b y pleth ysmographic recordings [Katayama, P. L ., et al 2017] .These pre -clinical 
studies support the hy pothesis that P2X3 antagonism could treat sleep disord ered breathing in 
patients with OSA.
As of 31 -AUG -2018, MK -7264 has been administered to 360 study  subjects in 12 completed 
and 2 ongoing (clinicall y complete) Phase 1 clinical trials. Single oral doses, 10 to 1800 mg, 
and multiple oral doses, 7.5 mg to 18 00 mg BID for up to 14 day s, were administered to 
healthy  subjects. The efficacy  of MK -7264 has been investigated in 11 completed Phase 2 
clinical trials. Eight of these trials included subjects with chronic cough; 2 studies were 
conducted in subjects with idiopathic pulmonary  fibrosis ( IPF) related cough . Efficacy  of 
MK-7264 was also evaluated in other indications, such as osteoarthritis pain, interstitial 
cystitis/bladder pain s yndrome, and asthma. Across studies, MK -[ADDRESS_1275495] common AEs being dose -dependent effects on taste sensation - eg, d ysgeusia, ageusia, 
hypogeusia. Subjects also described oral paresthesia (tingling sensation in the mouth and/or 
throat) and oral hy poesth esia (numbness/reduced sensitivity  often limited to a specific place 
in mouth, eg, side of the tongue, lip, back of throat) . The taste disturbance s and oral 
paresthesia/h ypoesthesia were fully and rapi[INVESTIGATOR_2478] y reversible after discontinuation of the drug.
Pharmacokinetics of MK -[ADDRESS_1275496] MK -7264 as approximately  64% of the MK -[ADDRESS_1275497] of 
elimination, with approximately  15% of an oral dose appearing in urine and feces as 
metabolites in healthy  adult male subjects. The exposure of MK -[ADDRESS_1275498]: MK-7264  27
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
2.5 Ongoing Clinical Studies
Approximately 2300 participants are to be enrolled in the ongoing MK -7264 clinical trials: 2 
Phase 1 studies (clinically complete), 3 Phase 2 studies (1 clinicall y complete) , and 3 Phase 3 
studies. 
Two ongoing Phase 1 studies are being conducted to evaluate the safet y, tolerability, and PK 
of MK -7264 in 46 healthy  adult male Japanese subjects , and to characterize the PK
performance of different formulations of MK -7264 , respectivel y.
Three Phase 2 studies are currentl y ongoing; one is evaluating the efficacy  of MK -7264 in 
the treatment of endometriosis related pain ( ERP); one is evaluating the efficacy , safet y and 
tolerability  of MK -[ADDRESS_1275499] on -going Phase 3 study  (in Japan onl y) is being 
conducted to evaluate the long -term safet y of MK -7264.
For more information, please refer to the MK -7264 I nvestigator’s Brochure.
2.6 Benefit/Risk Asse ssment
This study  is the first to test thepotential efficacy of MK-7264 in treating participants with 
moderate and severe OSA and will provide critical insights into the benefits and risks of 
MK-7264 compared to placebo . The benefit sfor participants with OSA from treatment with 
MK-7264 are unknown. The risk of OSA participants taking MK-7264 is also unknown .
However ,it is not anticipated that new safet y signals will emerge in this population. Additional 
details regarding specific benefits and risks for participants in this clinical study may be found 
in the accompan ying IB and informed co nsent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
Male/Female participants with moderate to severe obstructive sleep apnea between the ages 
of 18and 75 years(inclusive) will be enrolled in this study . 
  056LPF 
  05FQVP
PRODUCT: MK-7264  28
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Objectives Endpoints
Primary
•Primary  Objective:
•To evaluate the effect of multiple dose 
administration of MK -7264 on the Apnea 
Hypopnea Index (AHI) in participants 
with moderate to severe OSA without 
Positive Airway  Pressure (PAP).
•Primary  Hypothesis: 
•Multiple dose administration of MK -7264 in 
participants with moderate to severe OSA 
reduces the AHI relative to placebo. A 30% 
reduction in AHI as compared to placebo is 
expected.•Apnea -Hypopnea Index ( AHI)
change from baseline compared with 
placebo as calculated from 
polysomnograph y (PSG)
Secondary
•To evaluate the safet y and tolerability  of MK -
7264 in participants with moderate to severe 
OSA.•Adverse events, safet y laboratory 
assessments, ECGs and vital signs.
Exploratory
•To evaluate the pharmacokinetics of 
MK-7264 QHS in participants with moderate 
to severe OSA.•MK-7264 (plasma PK): Cmax, 
AUC0 -24, CL  and t1/2
•To evaluate arousal index following multiple 
dose administration of MK -7264 in 
participants with moderate to severe OSA.•Arousal Index
•To evaluate the proportion of stage N1 non -
REM sleep to TST following multiple dose 
administration of MK -7264 in participants 
with moderate to severe OSA.•Duration of stage N1 non -REM 
sleep to TST
•To estimate mean SaO2 during total sleep 
time (TST), NREM, REM, and awake time 
following the administration of multiple doses 
of MK -7264 in participants with moderate to 
severe OSA. •Mean SaO2 during TST, NREM, 
REM and awake time 
  056LPF 
  05FQVP
PRODUCT: MK-7264  29
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Objectives Endpoints
•To evaluate the proportio n of the night during 
TST and sleep stages in which SaO2 is less 
than 90% following multiple dose 
administration of MK -7264 in participants 
with moderate to severe OSA •Proportion of the night during TST 
and sleep stages in which SaO2 is 
less than 90%
•To evaluate loop gain following multiple dose 
administration of MK -7264 in participants 
with m oderate to severe OSA.•Loop gain
•To evaluate morning s ystolic and diastolic 
blood pressure following multiple dose 
administration of MK -7264 in participants 
with moderate to severe OSA.•Morning s ystolic and diastolic blood 
pressure
•To evaluate day time sleepi[INVESTIGATOR_908486] -7264 in 
participants with moderate to severe OSA.•Morning Sleep Questionnaire 
•Epworth Sleepi[INVESTIGATOR_7110] (ESS)
score (0 -24), units on a scale. 
•Functional Outcomes of Sleep 
Questionnaire (5- 20).
•To evaluate the performance of the Emerald 
Device to capture sleep data •Emerald Device sleep data 
•To eval uate blood and urine biomarkers •Exploratory  biomarkers
•To explore the relationship between genetic 
variation and response to the treatment(s) 
administered, and mechanisms of disease. 
Variation across the human genome may  be 
analyzed for association with clinical data 
collected in this study•Germline genetic variation 
  056LPF 
  05FQVP
PRODUCT: MK-7264  30
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275500] a PSG recording 
during Screening 2 where their diagnosis of OSA isconfirmed. 
The participants with confirmed OSA from Screening 2 will be asked to return to the clinic 
on Day  -15for Screening 3 . During Screening 3, the participants will undergo a second PSG
with supplemental inspi[INVESTIGATOR_908487] “chem oreflex 
dependent” . While asleep during the PSG, supplemental oxy gen will be delivered via face 
mask (40% inspi[INVESTIGATOR_1401]) as an addition to thestandard sleep stud y[Narkiewicz, K., et al 
2016] [Sands, S. A., et a l 2018] . In some participants t he addition of supplemental ox ygen 
will decrease carotid body hyperreflexia thereb y lowering loop gain andleading to reduced
AHI in those with “chemoreflex dependent” OSA .The number of AHI epi[INVESTIGATOR_1841] , as verified 
by a central reader will be determined. If the participant has a >30percent decrease in AHI 
events as well as airflow -based h ypopnea events (>30% reduction in airflow) that do not 
meet normal criteria (3% desaturation or arousal) compared to Screening 2 (see Operations 
Manual for details) , he/she will be eligible to be randomized into the study  and may return to 
the clinic on Day  -[ADDRESS_1275501] a baseline PSG and will receive study  
intervention for at- home dosing. Participants will begin self -administering study  drug at -
home (in the evening) for [ADDRESS_1275502] study  drug administration for a follow -up visit.
Because this is a Phase 1 assessment of MK-7264 in humans, the pharmacokinetic (PK) , 
pharmacod ynamic, and safet y profiles of the compound are still being elucidated. This 
protocol is therefore written with flexibility  to accommodate the inherent dy namic nature of 
Phase1 clinical studies. Refer to Section 8.[ADDRESS_1275503]: MK-7264  31
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275504] the efficacy  and safety  of MK -7264 in participants with 
chemoreflex -dependent (i.e. responsive to h yperoxia ) OSA. Th ese participants are 
specificall y predicted to respond to MK -[ADDRESS_1275505] for this population, 
screening PSG studies will be performed to confirm that each participant has OSA 
(Screening 2) and that the OSA is responsive to hy peroxia (Screening 3) prior to 
randomization .
Atwo-period crossover design was selected so that each participant receives both MK -[ADDRESS_1275506]. A 
baseline PSG is included in each period to control for an y period and /orcarry over effects that 
may be present. A dosing duration of approximately  [ADDRESS_1275507] a similar mechanism of action as OSA, after 4 day s of dosing (See 
Investigator’s Brochure). 
A single high MK-7264 do se (discussed in S ection 4.3) was selected to te stthe P2X3 
mechanism in OSA. 
Rationale for Amendment 039- 01: The original protocol, 039 -00, included a lower dose of 
MK-7264 of 45 mg to further assess dose -response . However, the 180 mg dose proposed was 
deemed sufficient to assess the objectives of the study . With the removal of the low dose, the 
study  design was altered to a 2 period cross over study  with decreased number of PSGs as 
well as other stud y related acti vities which improves the operational feasibility .
Rationale for Amendment 039- 02: Following publication of Protocol 039- 01, new data on in 
vitro testing of transporter inhibition by  [CONTACT_90338] -7264 became available . These data are 
described in Section 2.3 and ind icate the potential for inhibition of OA TP1B1/3, MATE1/2K 
and O CT1 at the [ADDRESS_1275508] of prohibited medications.
MK-7264 is a weak inhibitor of OATP1B1/3 and correspondin g increases in OATP1B1/[ADDRESS_1275509] . Pi[INVESTIGATOR_908488] a concomita nt medication 
from the protocol as its elimination is believed to be primaril y dependent on OATP1B1/3. 
Other statins are permitted without dose adjustment based upon the presence of alternate 
elimination pathway s (including OAT3 for rosuvastatin and pravastatin, CYP3A for 
simvastatin and atorvastatin, etc.) .
Potent MATE1/2K inhibitors result in less than three -fold increases in exposures of the 
substrate m etformin. As MK -[ADDRESS_1275510] of MK -7264 would 
be predicted to be significantly less (below two -fold), and therefore there are no exclusions 
or dose adjustments of MATE1/2K substrates. Potent inhibition of O CT1 has been reported 
to reduce metformin efficacy without increases in metformin exposure. MK -[ADDRESS_1275511]: MK-7264  32
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Efficacy and Safety Endpoints
One goal of the clinical development program for MK -7264 is to demonstrate its efficacy  in 
the treatment of OSA . The primary  efficacy  endpoint is the change from baseline in AHI. For 
this PoC study , the primary  efficacy  endpoi nt addresses a quantitat ive measurement of 
improved sleep that is calculated from data obtained from the PSG studies. This endpoint has 
been published as the primary  endpoint in many  trials in clinical development programs for 
OSA [Wellman, A., et al 2008] [Edwards, B. A., et al 2014] [Younes, M. 2014] [Paton, J. F. 
R., et al 2013] [Edwards, B. A., et al 2012] [Sands, S. A., et al 2018] .
The secondary objective is to evaluate the safety andtolerability  of MK -[ADDRESS_1275512] multiple co -morbidities as well as medications 
that may  influence the safety  of MK-7264. Therefore, adverse events, safety laboratory  
assessments, ECGs and vital signs will be captured (see S ection 8 for details) . 
The first exploratory  objective will evaluate the pharmacokinetics of MK -7264 QHS in 
participants with moderate to severe OSA. Due to the ex tensive experience with dosing 
MK-7264 in health y volunteers and trial participants a well- established PK model is 
available.  PK measur ement in this study  will help to develop PK/PD relationship sfor
various efficacy  and safety  endpoints .     
The second exploratory  endpoint is to evaluate the frequency  of nighttime arousals (as 
defined b y the arousal index) following multiple dose administration of MK -7264 in 
participants with moderate to severe OSA without PAP. Nighttime arousals in patients with 
OSA occ ur as a result of profound apnea and are a reflexive response to re -initiate breathing 
[Dempsey , J. A., et al 2014] . If MK -7264 ameliorates the number and/or severity  (duration 
and extent of hy poxia) of apnea ev ents, then a decrease in nighttime arousals should occur. 
The number of nighttime arousals is associated with the overall restorative capacity of sleep 
and can correlate with daytime sleepi[INVESTIGATOR_008], a significant quality of life measure for patients 
with OSA [Peppard, P. E., et al 2013] [Young, T., et al 2009] [Dempsey , J. A., et al 2014] . 
The third exploratory  endpoint is to evaluate the proportion of stage N1 non -REM sleep 
following multiple dose administration of MK -7264 in participants with moderate to severe 
OSA without PAP. Inparticipants with OSA , apneas are more commo n and severe during 
Stage N1 non -REM sleep [Sands, S. A., et al 2018] . Defining the proportion of TST a
participant is in stage N 1 non -REM and the number /severity of AHI events will be important 
to assess the efficacy  of MK -7264 in treating OSA.
The fourth exploratory  endpoint is to estimate mean ox ygen saturation (SaO 2) during total 
sleep time (TST), NREM, REM, and awake time following the administration of multiple 
doses of MK- [ADDRESS_1275513]: MK-7264  33
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275514] of multiple dose administration of 
MK-7264 in participants with moderate to severe OSA on the proportion of the total sleep 
time and sleep stage in which SaO2 is less than 90%. MK- 7264 should normalize carotid 
body  tone and minimize hy perventilation. By  [CONTACT_908510], MK -7264 
should decrease the number of reflective apneas that occur due to hypocarbia after 
hyperventilation. Decreasing the number and/or duration of the ap nea events should decrease 
the extent of hypoxia the participant experiences while treated with MK -7264. 
The sixth exploratory  endpoint is to evaluate loop gain following multiple dose 
administration of MK -[ADDRESS_1275515] an added benefit of normalizing blood pressure. 
The eighth exploratory  endpoint is to evaluate day time sleepi[INVESTIGATOR_908489] -7264 in participants with moderate to severe OSA without PAP. 
Daytime sleepi[INVESTIGATOR_127173] a significant morbidit y associated with OSA [Dempsey , J. A., et al 
2014] . If MK -7264 can decrease AHI and nighttime arousals, it should decrease the 
symptoms of day time sleepi[INVESTIGATOR_008]. Changes in day time sleepi[INVESTIGATOR_908490] (ESS), Morning Sleep Questionnaire and Functional Outcomes of Sleep 
Questionnaire (FOSQ) will be captured. 
The ninth exploratory  endpoint is to evaluate sleep endpoints using data gathered b y the 
Emerald Device (Section 8.2.2) .These may  include sleep staging, respi[INVESTIGATOR_697], AHI, and 
total sleep time.
The tenth exploratory  endpoint is to evaluate blood and urine biomarkers. These may  
include, but are not limited to, renin, angiotensin II, and vanilly lmandelic acid .
[IP_ADDRESS] Pharmacokinetic Endpoints
The relationship between MK -7264 plasma concentrations/exposure and AHI /side effects 
will be explored (as described above) . Exploratory  population PK anal yses will be conducted 
to obtain the exposure data in order to understand the exposure -response relationships 
between MK -7264 and efficacy  and safet y data.
[IP_ADDRESS] Pharmacodynamic Endpoints
No pharmacod ynamics biomarkers are planned for this study .  
  056LPF 
  05FQVP
PRODUCT: MK-7264  34
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_1275516] a participant’s response to therap y, susceptibility  to, severit y, 
and progression of disease. Variable response to therap y ma y be due to genetic determinants 
that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and I RB/IEC allow, a sample will be collected for DNA anal ysis 
from consenting participants.
DNA samples may be used for research related to the study  intervention( s), the disease under 
study , orrelated diseases. They  may  also be used to develop tests/assay s including diagnostic 
tests related to the disease under stud y, related diseases, and stud y intervention(s). Genetic 
research may  consist of the anal ysis of 1 or more candidate genes , the analy sis of genetic 
markers throughout the genome , or analy sis of t he entire genome. Anal ysis may  be 
conducted if it is hy pothesized that this may  help further understand the clinical data.
The samples may  be analy zed as part of a multi -study  assessment of genetic factors involved 
in the response to understand study  disea se or related conditions.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analy tes, depending on whi ch specimens are consented for 
future biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical r esearch is to explore and identify  biomarkers th at inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the corr ect drug/vaccine at the cor rect time. The 
details of this future biomedical r esearch substudy  are presented in Appendix 6.
4.2.[ADDRESS_1275517]: MK-7264  35
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
4.3 Justification for Dose
As this is a Phase 1 assessment of example in humans, and the PK, pharmacody namic and 
safet y profiles of the compound are still being evaluated, modifications to the dose or dosing 
regimen may  be required to achieve the scientific goals of the study objectives and/or to 
ensure appropriate safet y monitoring of the stud y participants. Details of allowed 
modifications are provided in Section 8.[ADDRESS_1275518] the 
dose for treatment of sleep apnea, prior exposure –response (cough rate reduction and taste 
disturbance) experience was leveraged, keepi[INVESTIGATOR_908491] -7264 
will increase the likelihood for increased incidence rate of taste disturbance, which could lead 
to participant non -acceptance, noncompliance and study  drop- out. The dose selected for the 
current stud y wasbased on the assumption: i) similarity  of the P2X3 -related mechanism of 
action for h ypersensitivity incondition sincluding sleep apnea and cough; ii) similar 
exposure -response between cough and sleep apnea and ;iii) as well as to mitigate potential 
rightward shift of exposure -response for sleep apnea to cough (ie, potential that sleep apnea 
is less sens itive than cough reflex). In efficacy  assessments of MK -[ADDRESS_1275519] near -maximal efficacy with an acceptable taste disturbance 
profile. To assess the efficacy  of MK -7264 for the treatment of sleep apnea, 180 mg qHS w as 
selected which provide s~[ADDRESS_1275520] increase 
(100%) in AUC on a 24 hour basis. The expected Cmax following 180 mg ( 1593 ng/mL ) is 
approximately  40% of that observed following 900 mg BID in a 14 day  multiple do se study  
(Cmax of 3960 ng/mL ). The assumption with th isqHS dose is that it provides higher 
exposure in the night time whe nthe efficacy  is most desirable and y et it maintains the 
concentrations that will be similar to 45 mg BIDduring the day  hours. The d ynamic 
concentration range with this dose relative to 45 mg BID dose is notexpected to substantially  
increase the likelihood of higher taste incidence ,as higher concentrations will be limited to 
only night time whe nthe subjects are asleep.
The appropriateness of the 180 mg QHS dose is also supported by [CONTACT_908511] , as the 
concentration range of 170-793 ng/mL was found to be efficacious in preclinical models for 
neuropathic, arthritic and inflammatory conditions and overlaps with the expecte d stead y 
state concentration in humans.
This dose will additionally provide important information on taste disturbance following 
QHS dosing regimen. The taste disturbance information available thus far is with BID dosing 
regimen and will not be relevant to extrapolate for the sleep apnea indication ,as the time 
course of the drug exposure will be different with the proposed QHS regimen compared to 
BID regimen. 
4.[ADDRESS_1275521]: MK-7264  36
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275522] to follow -up (ie, the participant is unable to be contact[INVESTIGATOR_530] b y the 
investigator) .
Astudy  may  be paused during review of newl y available preclinical/ clinical safet y, PK , 
pharmacod ynamic, efficacy , or biologic data or other items of interest, prior to a final 
decision on continuation or termination of the study. It may be necessary to keep the stud y 
open for gathering/reviewing of additional supportive data to optimally complete the 
objective(s) of the study . If necessary , the appropriate amendment(s) to the protocol and/or 
appropriate communication (s) will be generated. If the decision has been made to end th e 
study  following this review period, the study  end will be defined as the date of the Sponsor 
decision, and this end of study  date supersedes the definitions outlined above . The 
Competent Authority (ies) and Institutional Review Board(s)/Independent Ethics
Committee(s) [I RB(s)/ IEC(s)] will be apprised of the maximum duration of the study  beyond 
the last participant out and the justifica tion for keepi[INVESTIGATOR_271436] y open.
4.4.1 Clinical Criteria f orEarly Study Termination
There are no prespecified criteria for terminating the study  early.
5 STUDY POPULATION
Male/Female participants with moderate to severe obstructive sleep apnea between the ages 
of 18and 75 years(inclusive) will be enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study  if the participant :
1.Has an International Classification of Sleep Disorders (ICSD -3) diagnosis of Obstructive 
Sleep Apnea, based on:
i. Investi gator's assessment of the OSA history  and diagnostic interview, which 
must include: Documented sleep stud y (i.e. nighttime diagnostic PSG in a 
sleep lab or home sleep testing (HST) ) inthe pas t that confirmed the OSA
diagnosis without significant prior medical intervention including but not 
limited to: weight loss surgery  or other surgical interventions to improve 
sleep quality .
2.Has AHI ≥ 20events/hour at Screening 2.
3.Has not used positive airway  pressure devi ce (PAP) within the preceding 1 month or a 
dental appliance within the preceding 7 day s prior to Screening 2 Visit, and is not 
allowed to use PAP or a dental appliance throughout the study  (including washout 
intervals between treatment periods) and until the poststudy  visit. 
  056LPF 
  05FQVP
PRODUCT: MK-7264  37
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
4.Has hyperoxia response as assessed during Screening 3 hyperoxia challenge with a 
reduction in AHI of ≥30% as well as airflow -based hy popnea events (>30% reduction in 
airflow) that do not meet normal criteria (3% desaturation or arousal) upon supplemental 
oxygen therap y.
5.Has a baseline SpO2 ≥ 94% at Screening 1 to ensure that carotid body  response to 
hyperoxia is not impaired.
6.Has a Bod y Mass Index (BMI) ≤ 35 kg/m2 at the pre -study  (Screening 1) visit.
7.Is judged to be in good health based on medical history , physical examination, vital sign 
measurements, and laboratory  safet y tests (see Appendix 10.2) performed at the pre-
study  (Screening 1 , 2 or 3) visit and/ orBaseline 1 .Participant s with hypertension, Type 
2 diabetes, or hypoth yroidism may  be included if well-controlled on stable doses of 
appropriate therap y for ≥ 1 month prior to Screening Visit 2.
8.Has no clinicall y significant abnormality on electrocardio gram (ECG) performed at the 
pre-study  (Screening 1) visit and/or prior to administration of the initial dose of study 
drug.
Demographics
9.Ismale or female , from 18yearsto 75yearsof age inclusive, at the time of signing the 
informed consent.
Male Participants
10. Contraceptive use b y men should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studie s.
Female Participants
11. Contraceptive use b y women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.
•A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies:
-Is not a woman of childbeari ng potential (WOCBP)
OR 
  056LPF 
  05FQVP
PRODUCT: MK-7264  38
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
-Is a WOCBP and using an acceptable contraceptive method, or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long 
term and persistent basis), as described in Appendix 10.[ADDRESS_1275523] dose of study  intervention. The 
investigator should evaluate the potential for contraceptive method failure (ie, 
noncompliance, recentl y initiated) in relationship to the first dose of stud y 
intervention.
-A WOCBP must have a negative highly  sensitive pregnancy  test (urine as required b y 
local regulations) within [ADDRESS_1275524] cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy  test is required. I n such cases, the participant must be excluded from 
participation if the seru m pregnancy  result is positive.
•Additional requirements for pregnancy  testing during and after stud y intervention are 
located in Appendix 5.
•The inves tigator is responsible for review of medical history , menstrual history , and 
recent sexual activity  to decrease the risk for inclusion of a woman with an earl y 
undetected pregnancy .
Informed Consent
12. Provides written in formed consent/assent for the study . The participant may  also provide 
consent/assent for f uture biomedical r esearch. However, the participant may  participate 
in the main study  without participating in future biomedical research.
Additional Categories
13. Has a consistent sleep -wake schedule thatisnot subject to an y other unusual changes in 
sleepi[INVESTIGATOR_364361] (i.e., bedtimes and wake times do not vary  more than 1 -2hoursexcept 
on rare occasions) .
14. Is able to maintain sleep for at least 
4consecutive hours based on self -report.
5.[ADDRESS_1275525] be excluded from the study  if the participant:
Medical Conditions
1.Other than OSA, has evidence of another clinically significant, active pulmonary disorder 
such as bronchiectasis, emphy sema, or asthma documented by [CONTACT_969] , physical 
examination, or chest x -ray. 
  056LPF 
  05FQVP
PRODUCT: MK-7264  39
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275526] 6 months prior to the prestudy  visit or current 
evidence of an unstable or clinically significant cardiovascular disorder, including but not 
limited to:
 Acute coronary  syndrome
 Unstable angina
 Congestive heart failure
 Cardiogenic s yncope
 Cardiomy opath y
 Any symptomatic arrh ythmia
 Orthostatic hy potension
 Uncontrolled h ypertension
 Chronic kidney  disease
 Kidney  transplant
3.Has abnormal pre -randomization laboratory  values per the guidance below or other
clinically  significant, unexplained laboratory  abnormality  in the opi[INVESTIGATOR_1070]:
 Alanine transaminase (SGPT or ALT) > 1.5 x the upper limit of normal 
(x UL N)
 Aspartate transaminase (SGOT or AST) > 1.[ADDRESS_1275527]
 Direct bilirubin > 1.[ADDRESS_1275528]
 Serum Creatinine of > 2 mg/dL
See Appendix 2 for an algorithm for assessing out -of-range laboratory  values.
4.Has a history  or diagnosis of an y of the following conditions, in the opi[INVESTIGATOR_1070]:
 Narcoleps y(with or without cataplex y) or Idiopathic Hypersomnia
 Circadian Rhy thm Sleep Disorder 
  056LPF 
  05FQVP
PRODUCT: MK-7264  40
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
 Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking 
disorder, and REM behavior disorder
 Periodic L imb Movement (PL M) Disorder
 Restless L egs S yndrome
 Chronic Insomnia
5.Is aWOCBP who has a positive urine or serum pregnancy  test within 24 hours before the 
Baseline 1 of study  intervention (see Appendix 10.5). If the urine test cannot be 
confirmed as negative, a serum pregnancy  test is required. In such cases, the participant 
must be excluded from participation if the serum pregnancy result is positive.
6.Has a history  of clinically  significant or poorl y-controlled endocrine, gastrointestinal, 
cardiovascular, hematological, hepatic, immunological, rena l, respi[INVESTIGATOR_696] , genitourinary , 
or major neurological (including stroke and chronic seizures) abnormalities or diseases. 
Participants with a remote history  of uncomplicated medical events (eg, uncomplicated 
kidney  stones, as defined as spontaneous passage a nd no recurrence in the last 5 y ears, or 
childhood asthma) may  be enrolled in the stud y at the discretion of the investigator.
7.Is mentally  or legall y incapacitated, has significant emotional problems at the time of 
prestudy  (screening 1) visit or expected during the conduct of the stud y or has a history of 
clinically  significant psychiatric disorder. Participants who have had situational 
depression may be enrolled in the study  at the discretion of the investigator.
8.Has, in the opi[INVESTIGATOR_871], a history  or current evidence of any  condition, 
therap y, lab or ECG abnormality or other circumstances that might confound the results 
of the study , or interfere with the participant 's participation for the full duration of the 
study , such that it is not in the best interest of the participant to participate. Examples of 
excluded disorders include, but are not limited to: active endocrine disorders ( however, 
participant s with well -controlled non- insulin -dependent diabetes, or h ypothyroidism are 
allowed if on stable doses of appropriate therap y for ≥ 1month prior to Screening 
Visit 2).
9.Has an y history  of a neurological disorder, including but not limited to seizure disorder 
(other than single epi[INVESTIGATOR_908492]), stroke, transient ischemic
attack, multiple sclerosis, cognitive impairment, or significant head trauma with sustained 
loss of consciousness within the last 10 years
10.Has a history  of significant multiple and/or severe allergies (eg, food, drug, latex 
allergy ), or has had an anaphy lactic reaction or significant intolerability  (ie, sy stemic 
allergic reaction) to prescription or non -prescription drugs or food.
11.Has a h istory  of anaph ylaxis or cutaneous adverse drug reaction (with or without 
systemic s ymptoms) to sulfonamide antibiotics or other sulfonamide -containing drugs . 
  056LPF 
  05FQVP
PRODUCT: MK-7264  41
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
12.Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
13.Has a history  of cancer (malignancy ).
Exceptions: (1) Adequately  treated nonmelanomatous skin carcinoma or carcinoma in 
situ of the cervix or; (2) Other malignancies that have been successfully  treated with 
appropriate follow up and therefore unlikel y to recur for the duration of the study, in the 
opi[INVESTIGATOR_100892] (e .g., malignancies that
have been successfully  treated ≥10 y ears prior to the prestud y [screening] visit) .
14.Has an estimated glomerular filtration rate (eGFR) <60mL/min/1.73 m2based on the 
Cockcroft -Gault (CG) Equation.
Cockcroft -Gault Equation: 
ClCr=(140-age[yr ])(body wt [kg])
(72)(serum creat [mg/dL])
[Whe n creatinine is measure d in micromole/litre, u sethis formul a]
ClCr=(140-age[ yr])(bo dy wt[kg])
(72)(serum creatinine [mic romol/L] x 0.0113)
For females, multiple the result by 0.85.
At the discretion of the investigator a measured creatinine clearance, as determined by a 
24-hour urine collection, may  be used in place of, or in conjunction with, the estimate of the 
creatinine clearance.
Participants who have a measured creatinine clea rance of up to 10% below 60 mL /min may  
be enrolled in the stud y at the discretion of the investigator.
Prior/Concomitant Therapy
15.Is unable to refrain from or anticipates the use of certain medication s, including 
prescription and nonprescription drugs or he rbal remedies beginning approximately  2 
weeks (or 5 half -lives) prior to Screening 1, throughout the stud y (including washout 
intervals between treatment periods), until the poststudy visit. There may be certain 
medications that are permitted (see Section 6.5). A list of prohibited medications is
provided in the table below. The table below is not all inclusive and the participant may 
be excluded if taking other medications based on the discretion of the Sponsor or the 
Investigator. 
  056LPF 
  05FQVP
PRODUCT: MK-7264  42
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Table 1 Prohibited Medications and Specified Washout Period
Treatment Interval*
Investigational compounds 4 weeks prior to S creening 1or 5 half -
lives (see exclusion below )
Antihistamines (sedating) 2 weeks
Hypnotics (OTC as well as prescriptions) 2 weeks or 5 half -lives** prior to 
Screening 1
Other Psychotropi[INVESTIGATOR_1102]:
Antidepressants (other than fluoxetine)
Fluoxetine2 weeks
4 weeks
Anticonvulsants 2 weeks
Antipsychotics 2 weeks or 5 half -lives
Anxiolytics (benzodiazepi[INVESTIGATOR_1651], non-
benzodiazepi[INVESTIGATOR_1651])2 weeks or 5 half -lives
Centrally acting anticholinergics 2 weeks
Any CNS depressants 2 weeks
Mood Stabilizers 2 weeks
Stimulants 2 weeks
Supplements with possible psychotropic 
effects2 weeks
Other Medications:
Anticoagulants 2 weeks
Systemic glucocorticoids 2 weeks
Isotretinoin 2 weeks
Diet pi[INVESTIGATOR_3353] 2 weeks
Pi[INVESTIGATOR_2830] 1 week
* Interval notes minimum washout period. Washout should occur for 5 half -lives or the minimum 
specified period (2 or 4 weeks), which ever is longer to systematically eliminate the compound.
** The indicated hypnotic/anxiolytic washout applies to intermittent use only (defined as use of < 4 
times/week). For those participant s chronically using a hypnotic or anxiolytic (defined as use of ≥ 4 
times/week) a 4 -week washout (or 5 half -lives, whichever is greater) must occur prior to completion of 
Screening 1.Please see Section 6.5for more information.
Prior/Concurrent Clinical Study Experience
16.Has participated in another investigational study  within 4 weeks prior to the prestud y 
(screening 1) visit. The window will be derived from the date of the last visit in the 
previous study .
Diagnostic Assessments
None 
  056LPF 
  05FQVP
PRODUCT: MK-7264  43
PROTOCOL/AMENDMENT N O.:039-[ADDRESS_1275529] 1 week prior to stud y start.
Participant should not anticipate traveling across 3 or more time zones during the stud y.
20.Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately  
equivalent to: beer [354 mL /12 ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] 
[29.5 mL /1 ounce]) per day . Participants who consume 4 glasses o f alcoholic beverages 
per day  may  be enrolled at the discretion of the investigator.
21.Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately  equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day .
22.Is an excessive smoker (i.e., more than 10 cigarettes/day) and is unwilling to restrict 
smoking to ≤10 cigarettes per day  or is unwilling to follow the smoking restrictions 
defined b y the CRU. Participants who smoke ≤[ADDRESS_1275530] 1 unit of blood (approximately  500 mL ) or 
partici pated in another investigational stud y within 4 weeks prior to the prestudy 
(Screening 1) visit. The [ADDRESS_1275531] study 
procedure (i.e. poststud y, AE follow -up, etc.) in the previous study to the
prestudy /Screening 1 visit of the current study .
25.Is a regular user of cannabis, any  illicit drugs or has a history  of drug (including alcohol) 
abuse within approximately  3months. Participants must have a negative urine drug 
screen (UDS) prior to randomization.
26.Presents an y concern b y the investigator regarding safe participation in the study or for 
any other reason the investigator considers the participant inappropriate for participation 
in the study .
27.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study. 
  056LPF 
  05FQVP
PRODUCT: MK-7264  44
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
[IP_ADDRESS] Diet Restrictions
Fasting requirements for study  procedures, such as but not limited to laboratory safet y 
evaluations are specified in Section 8.0.
On PSG Assessment Visits , participants will fast from all food and drinks except water 
between stud y drug administration and t he next scheduled meal the following morning . 
Water will be provided during stud y drug administration. Water will be restricted 1 hour 
prior to and 1 hour after study  drug administration only  on PSG Assessment Visits .
On all visits, m eals and snack(s) will be provided by  [CONTACT_908512]. Participants will fast from all food and drinks except water between 
meals and snacks. At all other times and while at home, meals and snacks will be unrestricted 
in caloric content, composition and timing.
5.3.2 Caffeine, Alcohol ,and Tobacco Restrictions
[IP_ADDRESS] Caffeine Restrictions
Participants can consume c affeinated beverages or xanthine -containing products at their
normal daily  amount but not to exceed more than 6 units per day  amou nts (1 unit = 120 mg 
of caffeine). Participants should avoid drinking caffeinated beverages 4 hours before their 
anticipated bedtime at home . Caffeinated beverages will not be served to participants at the 
clinic prior to sleep stud y.Participants should n ot drink any  caffeinated beverages up to 10
hours prior to their scheduled in -clinic sleep stud y. 
[IP_ADDRESS] Alcohol Restrictions
Alcohol consumption is limited to no more than approximately  3 alcoholic beverages or 
equivalent (1 glass is approximately equivalent to : beer [354 mL /12 ounces], wine [118 mL/4 
ounces], or distilled spi[INVESTIGATOR_2120] [29.5 mL /1 ounce]) per day .Participants should avoid drinking 
alcoholic beverages 4 hours before their anticipated bedtime at home . Alcoholic beverages 
will not be served to participa nts at the clinic. Participants should not drink any  alcoholic 
beverages on the day  of their scheduled in -clinic sleep study .
5.3.3 Tobacco Restrictions
Smoking should be limited to ≤ [ADDRESS_1275532]: MK-7264  45
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
5.3.4 Activity Restrictions
Participants will avoid unaccustomed strenuous physical activity (ie, weight lifting, running, 
bicycling, etc.) from the prestudy  (Screening 1) visit until administration of the initial dose of 
study  drug, throughout th e study  (including washout intervals between treatment periods) and 
until the poststudy visit.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomized in the study . A minimal set of screen failure information 
may be included, as outlined in the electronic case report forms ( eCRF )entry  guidelines. 
Minimal information may include demograph y, screen failure details, eligibility  criteria, and 
any AEs or SAEs meeting report ing requirements.
5.5 Participant Replacement Strategy
If a participant discontinues from study  intervention OR withdraws from the study prior to 
completion of Period 2 a replacement participant may  be enrolled if deemed appropriate b y 
the investigator and Sponsor. The replacement participant will generall y receive the same 
intervention or intervention sequence (as appropriate) as the participant being replaced. The 
replacement participant will be assigned a unique treatment/randomization number. The 
study  site should contact [CONTACT_311652]’s 
treatment/randomization number.
The replacement participant may  begin dosing at the subsequent period/ dose, based on 
investigator and Sponsor review and discussion.
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study  participant according to 
the study  protocol .
Clinical supplie s MK-7264 and placebo will be packaged to support enrollment and 
replacement participants as required. When a replacement participant is required, the Sponsor 
or designee needs to be contact[CONTACT_26380]. Clinical supplies 
will be affixed with a clinical label in acc ordance with regulatory  requirement s.
6.1 Study Intervention(s) Administered
The study intervention (s) to be used in this study are outlined inTable [ADDRESS_1275533]: MK-7264  46
PROTOCOL/AMENDMENT N O.:039-02 
MK-7264 -039-02FINAL PROTOCOL 02-APR -2019
Table 2 Study Intervention s
Arm  
Nam eArm  
TypeIntervention 
Nam eTypeDose 
Form ulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Administra
-tionRegim en/
Treatm ent 
Period/
Vaccination 
Regim enUseIMP/
NIMPSourcing
PlaceboOther Placebo 
Matching 
MK-7264Other Tablet [ADDRESS_1275534] (IMP) and Non -Investigational Medicinal Product (NIMP) is based on guidance issued by [CONTACT_180620]. Regional and/or Country differences of the definition of IMP/NIMP may exist. In these circumstances, local legisl ation is followe d. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  47
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
All supplies indicated in Table 2 will be provided per the "Sourcing" column depending upon 
local country  operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/ba tch number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc).
Refer to Section 8.1.8 for details regarding administration of the study  intervention.
6.2 Preparation/Handling/Stora ge/Accountability
6.2.[ADDRESS_1275535] be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsibl e for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_63470] y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  [CONTACT_1034].
The investigator shall take responsibility  forand shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
interventions in accordance with the protocol and any applicable laws and regulations . 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  48
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Participants will be assigned randoml yto one of two treatment sequences according to a 
computer -generated allocation schedule.
The sample allocation schedules are shown below in Table 3 :
Table 3 Sample Allocation Schedule
Subjects Period 1 Period 2
N=8 Pbo MK-7264
N=[ADDRESS_1275536] based 
on evaluation of safet y, tolerability, and/or 
pharmacod ynamics data.
Note: Subjects who drop out will be replaced.
6.3.2 Stratification
No stratification based on age, sex, or other characteristics will be used in this study .
6.3.3 Blinding
A double -blinding technique with in -house blinding will be used. MK -7264 and placebo will 
be packaged identicall y so that blind is maintained. If applicable for certain site(s), 
MK-7264 and placebo will be packaged as open label bulk supplies and will be prepared 
and/or dispensed in a blinded fashion b y an unblinded pharmacist or qualified study site 
personnel. The participant, the investigator, and Sponsor personnel or delegate(s) who are 
involved in the study  intervention administration or clinical evaluation of the parti cipants ar e 
unaware of the intervention assignments.
6.4 Study Intervention Compliance
Interruptio ns from the protocol -specified treatment plan require consultation between the 
investigator and the Sponsor and written documentation of the collaborative decision on 
participant management.
6.5 Concomitant Therapy
If a participant does not discontinue all prohibited medications in Table 1 , he/she may  be 
included in the study  if the investi gator can rationalize that the specific use of a prior 
medication is either medically  required or not clinically  relevant within the context of the 
study . 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  49
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
Concurrent use of an y prescription or nonprescription medication, or concurrent vaccination, 
during t he ongoing stud y (ie, after randomization or intervention allocation) must first be 
discussed between the investigator and Sponsor prior to administration, unless appropriate 
medical care necessitates that therap y or vaccination should begin before the inv estigator and 
Sponsor can consult. The participant will be allowed to continue in the study if both the 
Sponsor and the investigator agree. The subject may  be asked to repeat a period or skip a 
period due to an y medical issues or concomitant medication use .
Paracetamol/acetaminophen or low dose non -steroidal anti- inflammatory  drugs 
(ibuprofen/naproxen) may be used for minor ailments without prior consultation with the 
Sponsor.
6.5.[ADDRESS_1275537] of this study .
If the below stoppi[INVESTIGATOR_4081], the study  will be p aused and no further dosing will occur 
until the Sponsor has reviewed the totalit y of data available. In order to continue the study 
(upon joint agreement with the Sponsor and investigator s), a substantial amendment will be 
submitted for approval.
1. An individual participant reports a Serious Adverse Event considered related to the 
study  drug b y the investigator.
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
Theemergency  unblinding call center will use the intervention allocation/randomization 
schedule for the study to unblind participants and to un mask study  intervention identity . The 
emergency  unblinding call center should only  be used in cases of emergency  (see Section 
8.1.10). The Sponsor will not provide random code/disclosure envelopes or lists with the 
clinical supplies. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  50
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275538] be collected through the participant’s last scheduled follow -
up, even if the pa rticipant has discontinued study  intervention. Therefore, all participants 
who discontinue study  intervention prior to completion of the protocol -specified treatment 
period/vaccination regimen will still continue to participate in the stud y as specified in
Section 1.[ADDRESS_1275539] 
occur. In addition, a participant may  be discontinued from study  intervention by  [CONTACT_19419], the stud y plan is violated, or 
for administrative and/or other safet y reasons. Specific de tails regarding procedures to be 
performed at study  intervention discontinuation are provided in Sections 8.1.[ADDRESS_1275540] be discontinued from study intervention but continue to be monitored in 
the study  for an y of the following reason s:
•The participant or participant’s legall y acceptable representative requests to discontinue 
study  intervention.
•The participant’s treatment assignment has been unblinded by [CONTACT_093], MSD 
subsidiary , or through the emergency  unblinding call center .
•The participant interrupts study  intervention administration for more than 2consecutive 
days or has 4 cumulative missed doses.
•The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, pla ced the participant at unnecessary  risk from continued 
administration of study intervention (including recommendation to discontinue 
participant from stud y treatment as part of monitoring for crystalluria/urolithiasis, see 
Section 8.4.6– Renal and Urologica l Safet y Procedures).
•The participant has a confirmed positive serum pregnancy test.
•The participant has a positive urine drug screen (confirmed by  [CONTACT_861182]) at any  time 
during the course of the study .
Discontinuation from study  intervention is “permanent.” Once a participant is discontinued, 
he/she shall not be allowed to restart stud y intervention . 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  51
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275541] be withdrawn from the study  if the participant or participant’s legall y 
acceptable representative withdraws consent from the study .
If a participant withdraws from the study, they will no longer receive stud y intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from th e 
study ,as well as specific details regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.9. The procedures to be performed should a participant repeatedl y fail 
to return for scheduled visits and/or if the study  site is unable to contact [CONTACT_111953] 7.3.
7.[ADDRESS_1275542] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The s ite must attempt to contact [CONTACT_19423]. I f the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally  equivalent methods). These contact [CONTACT_908513]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_11399] y qualified (by [CONTACT_8640], training, and experience) staff. Delegation of study  
site personnel responsibilities will be docu mented in the I nvestigator Trial File Bind er (or 
equivalent).
•All study -related medica l decisions must be made by  [CONTACT_19427] a qualified 
physician . 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  52
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investi gator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may  be utilized for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
•Additional evaluations/testing may  be deemed necessary  by [CONTACT_63519] y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional inform ed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accordance with those regulations.
The maximum amount of blood collected from each participant over the duration of the study
will not exceed 235mL(Appendix 10.8).
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirem ents) must 
obtain documented consent from each potential participant or each participant’s legall y 
acceptable representative prior to participating in a clinical study or future biomedical 
research .If there are changes to the participant’s status during the stud y (eg, health or age of 
majority  requirements), the investigator or medically  qualified designee must ensure the 
appropriate consent is in place.
[IP_ADDRESS] General Informed Consent
Consent must be documented by  [CONTACT_2299]’s dated signature [INVESTIGATOR_1660] b y the participant’s 
legally  acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated 
signature [CONTACT_63564].
A cop y of the signed and dated consent form should be given to the participant before 
partic ipation in the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the Institutional Review Board/Independent Ethics Committee’s 
(IRB/IEC’s )approval/favorable opi[INVESTIGATOR_19349]. The participant or his/her legall y 
acceptable representative should be informed in a timely  manner if new information becomes 
available that may  be relevant to the participant’s willingness to continue participation in the  
  056LPF 
  05FQVP
PRODUCT:   MK-7264  53
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
study . The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the participant’s dated 
signature [INVESTIGATOR_1660] b y the participant’s legally acceptable representative’s dated signature.
Specifics a bout a stud y and the study population will be added to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  qualified designee will explain the future biomedical r esearch 
consent to the participant, answer all of his/her questions, and obtain written informed 
consent before performin g any procedure re lated to the future biomedical research substudy . 
A cop y of the informed consent will be given to the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician ,to ensu re that the participant qualifies for the study.
8.1.[ADDRESS_1275543] information (including direct 
telephone numbers) to be used in the event of an emergency . The in vestigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of intervention randomization,
site personnel will add the treatment /randomization number to the participant identification 
card.
The participant identification card also contains contact [CONTACT_19430] a health care provider can obtain information about study 
intervention in emergen cy situations where the investigator is not available.
8.1.4 Medical History
A medical history  will be obtained by  [CONTACT_27404].
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use, including an y 
protocol -specified washout requirement, and record prior medication taken by  [CONTACT_88688] 14 day s before starting the stud y(Screening Visit 1).  
  056LPF 
  05FQVP
PRODUCT:   MK-7264  54
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
[IP_ADDRESS] Concomitant M edications
The investigator or qualified designee will record medication, if an y, taken by [CONTACT_63525] y.
8.1.[ADDRESS_1275544] not be re -used for 
different participants.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible partic ipants will be randomly  allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment randomization . Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
Administration of study  intervention will occur at home andin-clinic as described in Section 
1.3 Schedule of Activities. 
The distribution of study  intervention will be witnessed b y the investigator and/or qualified 
designee at the study visits. Participants will receive one bottle of stud y intervention at each 
baseline visit. Each bottle will contain MK-[ADDRESS_1275545] time of dosing in a drug diary .
Participants will return to clinic at t he end of each period for the assessment visit. If the visit 
assessment is delay ed by 1-2 day s as allowed in the Visit Window, the participant should 
continue study  intervention as instructed b y the site. During the assessment visit, participants 
will rece ive the assigned study  intervention in the evening, approximately  one and a half 
hour before bedtime. A dministration of study  intervention during in -clinic assessments will 
be witnessed b y the investigator and/or study staff.
Water will be provided during study  drug administration.  
  056LPF 
  05FQVP
PRODUCT:   MK-7264  55
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
While taking the study  intervention at home, p articipants who vomit after dosing or miss a 
dose should be instructed to continue with the next scheduled dose. However, on clinic PSG 
days, if the participant vomits within 1 hour of study drug administration, the participant 
should take an additional dose of study  intervention.  
[IP_ADDRESS] Timing of Dose Administration
Study  intervention will be administered orally  in the evening approximately oneand a half 
hours prior to bedtime.
8.1.[ADDRESS_1275546] notify the Sponsor when a participant has been 
discontinued/withdrawn from the study . If a participant discontinues for any reason at an y 
time during the course of the study , the par ticipant may  be asked to return to the clinic (or be 
contact[INVESTIGATOR_530]) for a poststudy visit as per the number of day s described in Section 8.12.4
(approximately  [ADDRESS_1275547] dose of study  intervention for a poststudy  visit ) to have 
the applicable procedures conducted. However, the investigator may  decide to perform the 
poststudy  procedures at the time of discontinuation or as soon as possible after 
discontinuation. I f the poststudy  visit occurs prior to the safet y follow -up time frame as 
specified in Section 8.4.1, the investigator should perform a follow -up telephone call at the 
end of the follow -up period ( Section 8.4.1) to confirm if any AEs have occurred since the 
poststudy  clinic visit. Any  AEs that are present at the time of discontinuation/withdra wal 
should be followed in accordance with the safet y requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may  withdraw their consent for future biomedical research. Participants may  
withdraw consent at an y time by  [CONTACT_111954] . If medical 
records for the main study are still available, the investigator will contact [CONTACT_111955] ([EMAIL_1250]). Subsequently, the 
participant's conse nt for future biomedical r esearch will be withdrawn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. I t is the responsibility  of the 
investigator to inform the participant of completion of withdrawal. An y analy ses in p rogress 
at the time of request for withdrawal or alread y performed prior to the request being received 
by [CONTACT_443171]. 
No new analy ses would be generated after the request is r eceived.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been completel y anon ymized, there wil l no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  56
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
8.1.10 Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNM ASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the intervention used by  a participant and/or the 
dosage administered, he/ she will contact [CONTACT_126537] a request for emergency  unblinding. As requested b y the investigator or medically  
qualified designee , the emergency  unblind ing call center will provide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contact[CONTACT_126538] a participant’s intervention assignment, the 
investigator who is qualif ied phy sician should make reasonable attempts to enter the intensit y
of the AEs observed, th e relation to study  drug , the reason thereof, etc., in the medical chart. 
If it is not possible to record this assessment in the chart prior to the unblinding, the 
unblinding should not be delay ed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency  unblinding has taken place, the investigator, site personnel, and Sponsor 
personnel may  be unblinded so that the appropriate follow -up medical care can be provided 
to the participant.
Participants whose treatment assignment has been unblinded by  [CONTACT_941] i nvestigator or medicall y 
qualified designee and/or non study  treating ph ysician must be discontinued from study  
intervention, but should continue to be monitored in the study.
8.1.11 Domicili ng
Participants will be instructed to report to t he sleep center on the evening of scheduled 
baseline and assessment visits as described in Section 1.3 . Participants will remain in the 
clinic overnight and will be discharged upon completion of assessments as described in 
Section 1.3. 
8.1.12 Calibration of Equi pment
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  57
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
8.2 Efficacy Assessmen ts
8.2.1 Polysomnogra phy
PSG is a diagnostic sleep study  that collects EEG, EOG, EMG, ECG, airflow, respi[INVESTIGATOR_418479], oximetry , and sleep position. The PSG will be used to assess entry into the study and 
will be used as an efficacy assessment at the time points indicated in the SoA . The details of 
the PSG procedure including participant preparation and lead placement will be described in 
the study  operations manual.
Sleep parameters including ,but not limited to , total sleep time (TST), Sleep L atency  (SL), 
Stage of Sleep (i.e. REM, non- REM), A rousal Index (AI) ,oxygen saturation (SaO 2), Apnea -
Hypopnea Index (AHI), and others will be calculated by  a central reader as described in the 
study  operations manual. 
The time of bedtime in the lab should approximate the participant ’s bedtime at home (median 
habitual bedtime), where "bedtime" is defined as the time when the participant
intends/attempts to fall asleep, e.g., l ying down or reclining with ey es closed. The median 
bedtime reported b y the participant at Screening 1(within ±1 hour) will be used as the 
bedtime ("Lights -Off") for all subsequent PSGs. During “Lights -On”, a trained study  staff 
will e nter the room to wake the patient (if applicable), stop the PSG recording, and turn on 
the light.   
Hyperoxia Challenge and Assessment of Loop Gain
AtScreening Visit 3 the PSG described above will be augmented using continuous 
supplemental inspi[INVESTIGATOR_1401] . The hy peroxia challenge is the addition of inhaled 40% 
oxygen delivered through a face mask. The AHI will be scored a s described above and 
compared to the number of AHI events as well as airflow -based hy popnea events (>30% 
reduction in airflow) that do not meet normal criteria (3% desaturation or arousal) (see 
Operations Manual for details) recorded at Screening Visit 2. If the AHI and/or airflow -based 
hypopnea events decreases by  30% between the two screening visits the participant will have 
aconfirmed hyperoxia response . 
8.2.2 Emerald Device Sleep Data Capture
For US sites with I RB approval (ex-US site(s) excluded) the Emerald device will be included 
during standard PSG for sleep data capture at screening, baseline, and assessment visits as 
described in the SoA . This device uses passive monitoring of radio wireless local area 
network (Wi -Fi)signals in combination with machine learning algorithms to determine
respi[INVESTIGATOR_908493], sleep stages, and periods of apnea. The concordance between Emerald-
derived endpoints and PSG measures will be explored. The details of the Emerald device 
procedure will be described in the S tudy Operations Manual. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  58
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
8.2.3 Morning Sleep Questionnaire (MSQ )
In each treatment period participants will be required to complete a morning sleep 
questionnaire to record items related to the previous night’s sleep . The MSQ should be 
completed in the morning, within [ADDRESS_1275548] be recorded on the MSQ (hour and minute) . The participants will be 
asked to complete the morning sleep questionnaire as indicated in the SoA. 
Participants will bring the completed questionnaires to clinic at assessment visits and the 
contents will be reviewed. Any participant who demonstrates non- compliance in completing 
the diary  in Period 1 should receive additional diary  training with emphasis on the 
importance of completing the diary  each morning .
8.2.4 Epworth Sleepi[INVESTIGATOR_7110] (ESS)
The ESS is a self -administered questionnaire designed to measure s leep propensity  in a
subjective but standardized way.The ESS consists of 8 que stions that take approximately  5 
minutes to answer. Participants will be asked to rate, on a 4- point scale (0 -3), their chances of 
dozing off or falling asleep while engaged in eight different situations that involve low levels 
of stimulation . The ESS score (the sum of 8 item scores, 0 -3) can range from 0 to 24. The 
higher the ESS score, the higher that person’s average sleep propensity in daily life (ASP). 
The participants will be asked to complete the ESS asindicated in the SoA.
8.2.5 Functional Outcomes of Sleep Questionnaire (FOSQ)
The FOSQ is a 30 item self-administered questionnair e which determine sfunctional status in 
adults; measures are designed to assess the impact of disorders of excessive sleepi[INVESTIGATOR_908494] b y 
effective treatment [Weaver, T. E., et al 1997] .The participants will be asked to complete the 
FOSQ as indicated in the SoA.
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amo unt of blood/tissue to be drawn/collected over the course of the stud y 
(from prestud y to poststudy visits), including approximate blood/tissue volumes 
drawn/collected by [CONTACT_126541], can be found in Appendix 8.
Planned time points for all safety assessments are provided in the SoA.
8.4 Physical Examinations
8.4.1 Complete Physical Examinations
A complete ph ysical examination will be conducted by [CONTACT_63534] (consistent with local requirements) as per in stitutional standard. At a minimum, the  
  056LPF 
  05FQVP
PRODUCT:   MK-7264  59
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
examination will include assessments of the following: general appearance; skin and 
lymphatic; ey es, ears, nose, throat; cardiovascular sy stem; respi[INVESTIGATOR_36517]; 
abdomen/gastrointestinal sy stem; urological s ystem; musculoskeletal and neurological 
systems. Other bod y systems may  be examined. Height (cm) and weight (kg) will also be 
measured and recorded.
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
8.4.2 Focused Physic al Examinations
A brief focused ph ysical examination will be conducted by [CONTACT_443162] y 
qualified designee (consistent with local requirements) as per institutional standard. At a 
minimum, the exam ination will include assessments of the foll owing : cardiovascular s ystem, 
respi[INVESTIGATOR_36517], abdomen/gastrointestinal s ystem, and extremities . Other bod y systems 
may be examined.
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
A brief focused ph ysical exam may  be performed at any  study  site visit that does not alread y 
include a ph ysical exam if deemed necessary  by [CONTACT_908514]/sy mptoms. A 
physical exam (complete or focused) can be performed at an y unscheduled visit if deemed 
necess ary by [CONTACT_093].
8.4.3 Calculate Body Mass Index
BMI will be calculated (weight/height2in kg/m2)by [CONTACT_908515]’s height and weight at Screening Visit 1 to ensure the participant meets 
study  Inclusion Criteria (see Section 5.1).   
8.4.[ADDRESS_1275549] and will 
include oral or t ympanic temperature (in centigrade), s ystolic and diastolic blood pressure 
(mm Hg), respi[INVESTIGATOR_2842], and heart rate (beats per minute). Vital signs should be performed 
prior to an y blood draws at the same timepoint. All blood pressure measurements during the 
study  should be performed on the same arm , preferably  by [CONTACT_3194].
Any clinically  significant abnormalities in vital signs noted after Screening Visit 1 will be 
recorded as AEs in the eCRF.
8.4.5 Electrocardiograms
For screening purposes, a single 12- lead electrocardiogram (ECG) will be obtained using 
local standard procedures and reviewed b y an investigator or medicall y qualified designee 
(consistent with local requirements) as outlined in the SoA. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  60
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
8.4.6 Renal and Urological Safety Procedures
Urinaly sis (including microscopy ) will be collected as out linedin the SoA. Participants who 
have either cry stals or unexplained hematuria will be further evaluated. The decision 
regarding continuing treatment with MK -7264 and/or continued participation in the study  
will be made on a case -by-case basis in consult ation with the Sponsor .
8.4.[ADDRESS_1275550] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically  qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record an y clinically 
relevant changes occurring during the study in the AE section of the case report form 
(CRF). The laboratory  reports must be filed with the source documents. C linically  
significant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judged b y the investigator to be more severe than expected for 
the participant's condition.
•All protocol -required laboratory  assessmen ts, as defined in Appendix 2, must be 
conducted in accordance with the local laboratory  manual and the SoA .
•If laboratory  values from nonprotocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in study  participant management or are 
considered clinically  significant by  [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
•For an y laboratory  tests with values considered clinically  signif icantl y abnormal during 
participation in the study  or within 14days after the last dose of stud y intervention , every  
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by  [CONTACT_093] . 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  61
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275551] be recorded on the diary . 
Participants will bring the diary  to clinic at assessment visits and the contents will be
reviewed. Any participant who demonstrates non -compliance in completing the diar y in 
Period 1 should receive additional diary  training with emphasis on the importance of 
completing the diary  each evening .
8.7 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 10.3.
Adve rse events, SAEs, and other reportable safety  events will be reported by  [CONTACT_2299] 
(or, when appropriate, b y a caregiver, surrogate, or the participant's legall y authorized 
representative).
The investigator and an y designees are responsible for detec ting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety  
events for outcome according to Section 8.4.[ADDRESS_1275552] to seriousness, 
intensity /toxicity  and causality .
8.7.1 Time Period and Frequency for Collectin g AE, SAE ,and Other Reportable 
Safety Event Information
AEs, SAEs, and other reportable safety  events that occur after the consent for m is signed but 
before intervention allocation/randomization, must be reported b y the investigator for 
randomized partici pants only  if the event is the result of a protocol -specified intervention, 
including but not limited to washout or discontinuation of usual therap y, diet, placebo 
treatment, or a procedure.
From the time of intervention allocation/randomization through [ADDRESS_1275553]:   MK-7264  62
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275554] be reported immediately  to the Sponsor 
if the event is considered related to study intervention .
Investigators are not obligated to activel y seek AE sor SAEs or other reportable safety  events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must prom ptly notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 4 .
Table 4 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -
specified 
Follow -up 
PeriodReporting Time 
Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame 
to Report 
Event and 
Follow -up 
Inform ation 
to Sponsor:
Nonserious Adverse 
Event (NSAE) Report if:
-due to protocol -
specified 
intervention
-causes 
exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data 
entry 
guidelines
Serious Adverse 
Event (SAE)Report if:
-due to protocol -
specified 
intervention
-causes 
exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes 
exclusionReport all Previously reported –
Follow  to 
completion/termination; 
report outcomeWithin [ADDRESS_1275555]:   MK-7264  63
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -
specified 
Follow -up 
PeriodReporting Time 
Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame 
to Report 
Event and 
Follow -up 
Inform ation 
to Sponsor:
Event of Clinical 
Interest (require 
regulatory reporting)Report if:
-due to 
intervention
-causes 
exclusionReport
- potential drug-
induced liver 
injury ( DILI )
- require 
regulatory 
reportingNot required Within [ADDRESS_1275556] (d o not 
require regulatory 
reporting)Report if:
-due to 
intervention
-causes 
exclusionReport
-non-DILI ECIs 
and those not 
requiring 
regulatory 
reportingNot required Within 5 
calendar 
days of 
learning of 
event
Cancer Report if:
-due to 
intervention
-causes 
exclusionReport all Not required Within 5 
calendar
days of 
learning of 
event
Overdos e Report if:
-receiving 
placebo run -in or 
other run -in 
medicationReport all Not required Within 24 
hours of 
learning of 
event
8.7.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safet y events. Open -ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.7.3 Follow -up of AE, SAE ,and Other Reportable Safety Eve nt Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safet y events ,
including pregnancy  and exposure during breastfeeding, events of clinical interest (ECI s), 
cancer, and overdose will be followed until resolution, stabilization, until the event is 
otherwise explained, or the participant is lost to follow- up (as defined in Section 7.3). In 
addition, the investigator will make eve ry attempt to follow all nonserious AEs that occur in
randomized participants for outcome. Further information on follow -up procedures is given 
in Appendix 10.3. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  64
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
8.7.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  [CONTACT_908516] y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
Sponsor will comply  with country -specific regulatory  requirements and global laws and 
regulations relating to safe ty reporting to regulatory authorities , IRB/IECs, and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to inv estigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify  the IRB/IEC, if appro priate according to local requirements.
8.7.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant exposure during breastfeeding are not considered AEs, an y 
pregnancy  or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the stud y are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortio n, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported .
8.7.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not Applicable
8.7.[ADDRESS_1275557] (ECI s)
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.
Events of clinical interest for this study  include: 
1.An overdose of Sponsor's product, as defined in Section 8. 8, that is not associated with 
clinical symptoms or abnormal laboratory  results. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  65
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275558]  of protocol- specified 
laboratory  testing or unscheduled laboratory  testing.*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that must trigger 
an additional evaluation for an underl ying etiology. The study  site guidance for 
assessment and follow up of these criteria can be found in the Investigator Study  File 
Binder (or equivalent).
It may  also be appropriate to conduct additional evaluation for an underl ying etiology  in th e 
setting of abnormalities of liver blood tests including AST, ALT, bilirubin, and alkaline 
phosphatase that do not meet the criteria noted above. In these cases, the decision to proceed 
with additional evaluation will be made through consultation between the study  investigators 
and the Sponsor Clinical Director. However, abnormalities of liver blood tests that do not 
meet the criteria noted above are not ECIs for this study.
8.8 Treatment of Overdose
The participant has taken (accidentally or intentionally) any drug administered as part of the 
protocol that exceeds the dose as prescribed b y the protocol. I t is up to the investigator or the 
reporting ph ysician to decide whether a dose is to be considered an overdose, in consultation 
with the Sponsor.
8.9 Pharmacok inetics
8.9.1 Bloo d Collection for Plasma MK -7264
Sample collection, storage, and shipment instructions for plasma samples will be provided in 
the study  operations manual .     
8.10 Planned Genetic Analysis Sample Collection
This sample should be drawn for planned analysis of the association between genetic variants 
in DNA and drug response. This sample will not be collected at the site if there is either a 
local law or regulation prohibiting collection, or if the I RB/IEC does not approve the 
collection of the sample for these purposes. If the sample is collected, leftover extracted 
DNA will be stored for future biomedical research if the subject signs the FBR consent. If the 
planned genetic anal ysis is not approved, but FBR is approved and consent is given, this 
sample will be collected for the purpose of FBR .
Sample collection, storage, and shipment instructions for planned genetic analysis samples 
will be provided in the operations/laboratory manual. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  66
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
8.11 Future Biomedical Researc h Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
•Leftover DNA for future research
•Leftover main study  urine from clinical biomarkers assay  
•Leftover main stud y serum from clinical biomarkers assay 
•Leftover main stud y plasma from clinical biomarkers assay
8.[ADDRESS_1275559] demonstrate AHI ≥ 20
events/hour to continue in the 
study . 
During Screening Visit 3 participants will undergo a PSG with hy peroxia challenge to 
confirm presence of loop gain. Participants demonstrating a 30% reduction in AHI during 
hyperoxia challenge will be randomized into the study .  
Participants may  be rescreened after consultation with the Sponsor. Rescreening should 
include all screening procedures listed in the SoA, including consent review. 
8.12.[ADDRESS_1275560] a baseline PSG and will receive study 
intervention for at- home dosing. Participants will begin self -administering study  drug at -
home (in the evening) for 6-d ays. Participants will return to the clinic on Day [ADDRESS_1275561]:   MK-7264  67
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275562] study  clinic visit.
8.12.5 Critical Procedures Based on Study Objectives: Timing of Procedure
For this study , the PSG is the critical procedure.
At any  postdose time point, the PSG needs to be started as close to the exact start time
relative to dosing as possible. All other procedures should be performed as close to the 
prescribed/scheduled time as possible. Study  procedures can be performed prior or after the 
prescribed/scheduled time.
The order of priorit y can be changed during the study  with joint agreement of the investigator 
and the Sponsor Clinical Director.
Any nonscheduled procedures required for urgent evaluation of safet y concerns take 
precedence over all routine scheduled procedures.
The following variance in procedure collection times will be permitted.
•PSG Lights-Off Time for Baseline and Assessment Visits (+ /-1 hour )
•Predose 
PKCollection: - 60 minutes from scheduled time within PSG day
•Postdose 
PKCollection: + 60 minutes from scheduled time within PSG day
•Laboratory  Safet y Tests: + 120minutes from scheduled time within PSG day
•Predose Vital Signs: -
60 minutes from scheduled time within PSG day
•Postdose Vital Signs: +[ADDRESS_1275563]:   MK-7264  68
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
8.12.6 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a Phase 1 assessment of MK- 7264 in sleep apnea participants , and the PK, 
pharmacod ynamic, and safet y profiles of the compound is still being elucidated. This 
protocol is written with some flexibility  to accommodate the inherent d ynamic nature of 
Phase 1 clinical studies. Modifications to the dose, dosing regimen, and/or clinical or 
laboratory  procedures currentl y outlined may be required to ach ieve the scientific goals of 
the study  objectives and/or to ensure appropriate safet y monitoring of the study participants.
As such, some alterations from the currentl y outlined dose and/or dosing regimen may be 
permitted based on newly available data, but the maximum daily  dose may  not exceed those 
currentl y outlined in the protocol.
•Entire period(s) may  be omitted or repeated
•Decrease in the duration of study  intervention administration (eg, number of day s)
•Lengthening of the wash- out period between doses
•Addition of trial pause to assess efficacy and/or safety
•Instructions to take study intervention with or without food or drink may be modified 
based on newl y available data
•Modification of the sample processing and shippi[INVESTIGATOR_908495] y available data
•Modification or removal of the Emerald Sleep Capture Device 
•Modification, removal , or decision not to anal yzethe clinical biomarkers 
•Maximum Body  Mass Index (BMI) for inclusion criteria may  be reduced
If necessary ,a participant must be discontinued for the reasons described in Section 7.
If it is determined that incomplete or aberrant data has been captured during the baseline 
and/or assessment PSG at any  post -randomization study  visit, the participant may  be asked to 
repeat the baseline and/or assessment PSG or the entire treatment period. 
The window between screening visits, the window between Screening Visit [ADDRESS_1275564]:   MK-7264  69
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
participant’ s cumulative exposure and/or may  increase the total blood volume by 74mL per 
repeated period and 37 mL per repeated PSG . The resulting exposure or blood volume 
increases will be deemed acceptable b y the Sponsor and investigator for that participant. The 
total blood volume should remain <500 mL. If there are >2 failed PSGs or >[ADDRESS_1275565] b e detailed b y 
the Sponsor in a letter to the Study  File and forwarded to the investigator for retention. The 
letter may  be forwarded to the I RB/IEC at the discretion of the investigator .
9 STATISTICAL ANALYSIS PLAN
9.1 Statistical Analysis Plan Summary
The anal ysis for the primary  endpoint will be on the natural log scale of the AHI data. 
Natural log -transformed fold change from baseline values for AHI willbe anal yzed using a 
linear mixed effects model. The dependent variable is natural log ( treatment/baseline) , and 
the independent variables in the model include terms for treatment, sequence, and period. In 
addition, the between -treatment difference in baseline AHIs (Xdiff_AB = ln(baseline of MK -
7264/baseline of Placebo)) will be used as a covariate in the mode l, along with a treatment by 
[CONTACT_908517]_AB interaction; the latter term allows for the fact that the correlation between change 
from baseline and baseline may  differ b y treatment. An unstructured covariance matrix will 
be used to allow for unequal treatment var iances and to model the correlation between 
treatment measurements within each subject via the REPEATED statement in SAS PROC 
MIXED. Least square means and 95% confidence intervals will be calculated for each 
treatment. These least square means and 95% CIs will be exponentiated to obtain the 
geometric mean fold change from baseline for each treatment. The least square mean 
treatment differences (MK -7264 - Placebo) and corresponding 90% CIs in natural log 
transformed change from baseline will be calculated f rom the model. The treatment 
differences and CIs will be exponentiated to obtain the geometric mean treatment fold 
differences (MK -7264/placebo) and corresponding CIs.  If the upper limit of this 90% CI  is 
less than 1.00, then it will be concluded that the administration of MK -[ADDRESS_1275566]:   MK-7264  70
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
9.3 Hypotheses/Estimation
Primary :
Hypothesis: Multiple dose administration of MK -7264 i n participants with moderate to 
severe OSA reduces the AHI relative to placebo. A 30% reduction in AHI as compared to 
placebo is expected.
Secondary :
Objective: To evaluate the safet y and tolerability  of MK -7264 following multiple dose 
administration of MK -7264.
Exploratory Objectives:
To evaluate the pharmacokinetics of MK -7264 in participants with moderate to 
severe OSA.
To evaluate arousal index following multiple dose administration of MK -7264 in 
participants with moderate to severe OSA .
To evaluate the proportion of stage N1 non- REM sleep following multiple dose 
administration of MK -7264 in participants with moderate to severe OSA .
To estimate mean SaO2 during total sleep time (TST), NREM, REM, and awake time 
following the administration of multiple doses of MK- 7264 in participants with 
moderate to severe OSA. 
To evaluate the proportion of the night during TST and sleep stages in which SaO2 is 
less than 90% following multiple dose administration of MK- 7264 in participants 
with moderate to severe OSA 
To evaluate loop gain following multiple dose administration of MK -7264 in 
participants with moderate to severe OSA .
To evaluate morning s ystolic and di astolic blood pressure following multiple dose 
administration of MK -7264 in participants with moderate to severe OSA .
To evaluate day time sleepi[INVESTIGATOR_908496] -7264 
in participants with moderate to severe OSA .
To evaluate the performance of the Emerald Device to capture sleep data
To evaluate blood and urine biomarkers 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  71
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
To explore the relationship between genetic variation and response to the treatment(s) 
administered, and mechanisms of disease. Variation across the human ge nome may  
be anal yzed for association with clinical data collected in this study
9.4 Analysis Endpoints
Primary :
AHI, which is sum of the apnea and h ypopnea indices, is the primary outcome measure. The 
apnea index for each participant will be calculated as the number of apneas divided by [CONTACT_908518]. The hypopnea index for each participant is calculated as the number of 
hypopneas divided by  [CONTACT_908519]. The AHI will be calculated as the number of 
apneas and h ypopneas divided by  [CONTACT_908519] . Baseline AHI for each period are 
obtained on Day -1.  Individual AHI fold -change from baseline in each treatment period will 
be calculated as the ratio (on- treatment AHI/baseline AHI).
Secondary :
Adverse experiences and othe r safet y measurements (e.g., vital signs, ECGs, laborat ories)
Exploratory Endpoints:
MK-7264 (plasma PK): Cmax, AUC0- 24, CL ,and t1/2
Arousal Index for TST, REM, and NREM
Mean SaO2 for TST, REM, NREM, and Awake time .Baseline mean SaO2 for each 
period is obtained on Day -1.  Individual mean SaO2 fold -change from baseline in 
each treatment period will be calculated as the ratio (on- treatment mean 
SaO2/baseline mean SaO2).
Proportion of the night during TST, REM, NREM, and Awake time in which SaO2 
<90%.
Proportion of stage N1 non -REM to TST
Loop Gain at various sleep stages
Change in Sy stolic and Diastolic blood pressure (BP at Lights on –BP at -1 .5hr)
ESS, Morning Sleep Questionnaire (MSQ) , and FOSQ scores
Emerald Device sleep data (Not in the scope of the current anal ysis plan.  A separate 
statistical analy sis planwill be drafted, and a separate memo will be prepared ) 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  72
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
9.5 Analysis Populations
The following populations are defined for the analysis and reporting of data.  All participants
will be reported, and their data analy zed, according to the treatm ent(s) they actuall y received.
All Participant s as Treated (ASaT): The All Participants as Treated Population consists of al l
participants who received at least one dose of treatment.  This population will be used for 
assessments of safety  and tolerability .
Per-Protocol (PP) : The Per -Protocol Population consists of t he set of data generated by [CONTACT_908520], according to the underl ying scientific model. 
Compliance covers such considerations as exposure to treatment, availability of 
measurements and absence of important protocol deviations.  Important protocol deviations 
will be identified to the extent possible prior to unblinding by [CONTACT_100935]/compliance, and its analysis and interpretation.  An y participants or data values 
excluded from anal ysis will be identified, along with the ir reason for exclusion, in the CSR.  
At the end of the stud y, all participants who are compliant with the study procedure as 
aforementioned and have available data from at least one treatment will be included in the 
Per-Protocol dataset. This population w ill be used for the PK and efficacy  analyses.
9.[ADDRESS_1275567] comparing 180mg MK -7264 versus 
placebo using data from all two periods.  The dependent variable is natural log 
(treatment/baseline), and the independent variables in the model include terms for treatment, 
sequence, and period. In addition, the between -treatment difference in log -baseline AHIs 
(Xdiff_AB = ln(baseline of MK -7264/baseline of Placebo)) will be used as a covariate in the 
model, along with a treatment by  [CONTACT_908517]_AB interaction; the latter term allows for the fact that 
the correlation between change from baseline and baseline may differ b y treatment. An 
unstructured covariance matrix will be used to allow for unequal treatment variances and to 
model the correlation between treatment measurements within each subject via t he 
REPEATED statement in SAS PROC MI XED. If the model fails to converge a simpler 
covariance structure, Ty pe=CS, will be used. Kenward and Roger's method will be used to 
calculate the denominator degrees of freedom for the fixed effects (DDFM=KR).  Least 
square means and 95% confidence intervals will be calculated for MK -[ADDRESS_1275568] squares means and 95% CIs will be exponentiated to obtain the geometric mean 
fold change from baseline for each treatment.  The least squares mean treatment di fference 
(MK- 7264 - Placebo) and corresponding 90% CI in natural log transformed change from 
baseline will be calculated from the model. The treatment difference and CI will be  
  056LPF 
  05FQVP
PRODUCT:   MK-7264  73
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
exponentiated to obtain the geometric mean treatment fold difference (MK -7264/placebo) 
and corresponding CI.  If the upper limit of this 90% CI  is less than 1.00, then it will be 
concluded that the administration of 180 mg MK -7264 has statistically  significantly  lowered 
the AHI, thus satisfy ing the primary  hypothesis. This CI  will be examined for the 
containment of 0.70 which translates into a 30% reduction in AHI with treatment. 
PROC MIXED DATA=all;
CLASS seq prd trt subjid;
MODEL log(value/ base) = seqtrtprdxdiff_AB xdiff_AB*trt/ ddfm=kr; 
  REPEATED trt/SUBJECT= subjid(se q) TYPE=UN;
LSMEANS trt/AT xdiff_AB=0 DIFF CL ALPHA=0.1;
RUN;
The posterior probability that the true mean percent reduction in AHI after multiple doses of 
MK-7264 compared to placebo exceeds 10, 20, 30, 40 and 50% will also be obtained, 
assuming normali ty and a non -informative prior.
Secondary Endpoints
Safety  and tolerability  will be evaluated following multiple doses of MK- 7264 administered 
to the participants with OSA by  [CONTACT_908521] y 
measurements (vital signs, ECGs, laboratories). Summary  statistics will be provided as 
appropriate.
Exploratory Endpoints
Population pharmacokinetics approach will be utilized for evaluating MK-7264 plasma PK 
parameters, Cmax, AUC0- 24, CL , and t1/2 . The population PK results will be presented in a 
separate memo.
Mean SaO2 : The anal ysis for the mean SaO2 will be on the natural log scale.  Natural log -
transformed fold change from baseline values for mean SaO2 will be analyzed using the 
above described model. Baseline is defined as the mean SaO2 during total sleep time on day -
1 for each period.  The mean SaO2 during REM, NREM and Awake time will be anal yzed in 
a similar fashion. 
Proportion of the Night SaO2 <90%:Summary  statistics will be provided for the percentage of 
participant s who experience a SaO2 level less than 90% during the TST by [CONTACT_3148].
Summary  statistics will also be provided for the proportion of the night during total sleep 
time in whi ch SaO2 is <90% by [CONTACT_3148]. The proportion of the night SaO2<90% during 
various sleep stages, REM, NREM, and Awake time will also be summarized.
Descriptive summary  statistics will be provided for the following ex ploratory  endpoints 
including arousal index, loop gain at various sleep stages , and proportion of stage N1 NREM 
to TST . Some of these parameters may  alsobe analy zed in models as previously  described to 
explore the effect of MK -[ADDRESS_1275569]:   MK-7264  74
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
To assess the day  time sleepi[INVESTIGATOR_908497], descriptive statistics will 
be provided f or ESS, MSQ , and FOSQ scores. The relationship between the AHI and loop 
gain at different sleep stages and the relationship ofAHI and various scores (ESS, MSQ , and 
FOSQ) will be explored graphicall y.  
To explore the effect of MK -7264 on diastolic (DBP) and s ystolic blood pressure (SBP), the 
difference (BP at Lights on –BP at -1 .5hr) will be computed on the original scale.  Summary  
statistics for this difference in the BP for both diastolic and systolic blood pressure readings 
willbe computed.
Analy sis of the sleep data from Emerald device will not be a part of the current anal ysis plan . 
A separate statistical plan will be drafted, and the results of the anal ysis will be presented in a 
separate memo.
Analy sis of blood and urine biomarkers and t he evaluation of the relationship of genetic 
variation and response to the treatment and mechanism of disease will not be a part of current 
analysis plan.  Results of these anal ysis may be presented in a separate memo.
All data will be examined for departures from the assumptions of the model(s), i.e., 
heteroscedasticity , outliers, and non -independence and nonnormalit y of the error terms.
Suitable data transformations may  be applied. Distribution -free methods may be used if a 
serious departure from the assumptions of the model(s) is observed.
Individual listings for each of the endpoints by [CONTACT_141721]. Baseline 
summary  statistics will also be provided.
9.7 Interim Analyses
No Interim anal yses are planned
9.8 Multiplicity
No multiplicity  adjustment procedure will be applied, as there is onl y one hypothesis to be 
tested
9.9 Sample Size and Power Calculations
Primary  endpoint: AHI 
A study  with 1 6completing subjects in a 2- period crossover design has ~9 2% probability  to 
detect (alpha=0.05, 1- sided) a statisticall y significant difference between treatments if the 
true underl ying geometric -mean ratio, GMR (MK7264/Placebo), is 0.70 (which translates 
into a 30% reduction in AHI after treatment with MK -7264 co mpared to placebo). This 
estimate is based on 2 000 simulated trials of size N=1 6in which individual AHI values were 
generated assuming a true reduction in AHI of 30%, total variance of 0.36 (natural log scale) 
and between- measurement correlation of 0.75. These variance estimates were obtained from 
MK-[ADDRESS_1275570]:   MK-7264  75
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
with the above -described linear mixed effects model. The power was obtained as the 
percentage of trials showing a statisticall y significant between -treatment difference.
Power calculations
Sample size GMR=0.70
30% reduction
Correlation=0.75GMR=0.70
30% reduction
Correlation=0.60GMR=0.70
30% reduction
Correlation=0.50
N=[ADDRESS_1275571]:   MK-7264  76
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_1275572] for Clinical Trials
[COMPANY_006] Sharp and Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials th at are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry c riteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary consider ations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol an d general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per M SD policies and 
procedures, if fraud , scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues 
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified . 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  77
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically a ppropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing , in such cases, publ ication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the re commendations published by [CONTACT_908522] e of 
Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona lReview Board [IRB ]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by [CONTACT_2717]/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by [CONTACT_63543], except 
changes required urgently to prot ect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the participant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All participation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influe nce on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], only the investigator, Sp onsor (or representative), ethics committee, and/or regulatory authorities will have 
access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protoc ol and informed consent authorized by [CONTACT_63544] c ommittee.
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair man ner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, M SDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible participants. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  78
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consiste nt with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (eg, to scie ntific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protoco l, agree to support these et hical and scientific standards .
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/ subinvestigator(s) agree, if requested by  [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statem ents. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmis sion of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by  [CONTACT_1034]. Any  participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical re cords may  be examined by  [CONTACT_126560] S ponsor, by  
[CONTACT_6667]/IEC members, and b y inspectors from regulatory authorities. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  79
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the invest igator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by [CONTACT_093], except to the extent that it is included in a 
public ation as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  cons ult and/or cop y study  documents to 
verify  worksheet/ CRF data. By  [CONTACT_17317], the participant agrees to this 
process. If study  documents will be photocopi[INVESTIGATOR_75311]/ CRF information, the participant will be ide ntified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all ap plicable privacy  laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC mee ts 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies .
10.1.[ADDRESS_1275573]:   MK-7264  80
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275574] (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determining whether the stud yand its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as S ponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to iden tify potentiall y appropriate studies for their 
disease conditions and pursue participation b y calling a central contact [CONTACT_126563].
By [CONTACT_12570], the investig ator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive ,or other locally  mandated registries are that of the 
Sponsor and agrees not to submit any  information about this study  or its results to those 
registries.
10.1.[ADDRESS_1275575] the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International Conference on Har monization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally  
accepted standards of GCP ); and all applicable federal, state and local laws, rules and 
regulations relating to the condu ct of the clinical study .
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored b y MSD, is provided i n this appendix 
under the Code of Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform t he Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulti ng 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  [CONTACT_908523]’s studies. The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in  
  056LPF 
  05FQVP
PRODUCT:   MK-7264  81
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275576] 
of the investigator’s knowledge, threatened .
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct by  
[CONTACT_55896] y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and prov ide direct access to source data documents.
Study  documentation will be promptly  and fully  disclosed to the Sponsor by [CONTACT_63551], 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to co nfirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the cur rently approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or part y without written notification to the Sponsor .
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study  records that include al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible,  
  056LPF 
  05FQVP
PRODUCT:   MK-7264  82
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry , and should be explained if necessary  (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study . Also, current medical records must be available .
10.1.9 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor p rematurel y terminates a particular stud y site, the Sponsor will 
promptly  notify  that study  site’s IRB/IEC . 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  83
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in Table 5will be performed b y the local laboratory .
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5of the protocol.
•Additional tests may  be performed at an y time during the study as determined necessary 
by [CONTACT_43215].
Table 5 Protocol -required Safet y Laboratory  Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count RBC Indices:
MCV
MCHWBC count with Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Chemistry Blood Urea Nitrogen 
(BUN)/UreaPotassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic -Oxaloacetic 
Transaminase (SGOT)Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
elevated above the 
upper limit of normal)
Albumin Bicarbonate Chloride Phosphorus
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase (SGPT)Total Protein
Glucose nonfasting Calcium Alkaline phosphatase
Routine Urinalysis• Specific gravity
• pH, glucose, protein, blood, ketones, [bilirubin, urobilinogen, nitrite, leukocyte esterase] 
• Microscopic examination 
Other Screening 
Tests• Follicle -stimulating hormone (as needed in women of nonchildbearing potential only)
• Alcohol and drug screen (to include at minimum: amphetamines, barbiturates, cocaine, 
opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651]) if applicable
• Urine/Serum β human chorionic gonadotropin (β hCG) pregnancy test (as ne eded for 
WOCBP)
• Serology (HIV antibody, hepatitis B surface antigen [HBsAg], and hepatitis C virus antibody)
NOTES:
The i nvestigator (or medically  qualified designee) must document their review of each 
laboratory  safet y report. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  84
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whethe r or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study inter vention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s 
product) includes an y pharmaceutical product, biological product, vaccine, diagnostic 
agent, or protocol specified procedure whether investigational or marketed (including 
placebo, active comparator product, or run -in intervention) , manufactured by , licensed 
by, provided by , or distributed by  [CONTACT_63553] .
Events meeting the AE definition
•Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the medical 
and scientific judgment of the investigato r.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
•New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been prese nt before the start of the study .
•Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.” 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  85
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
•Surgery  planned prior to informe d consent to treat a pre -existing condition that has not 
worsened.
•Refe r to Section 8.4.[ADDRESS_1275577] medical occurrence that, at any dose:
1. Results in death
2. Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
3. Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay , even 
if the hospi[INVESTIGATOR_2138] a precautionary  measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing condition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history .
4. Results in persistent or significant disability/incapacity
•The term disability  means a substantial disruption of a person’s ability  to conduct 
norm al life functions. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  86
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
•This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
5. Is a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagnosis.
6. Other important medical events
•Medical or scientific judgme nt should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_908498] e medical or surgical intervention to prevent 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported in the Same Manner as SAE
Additional events that require reporting in the same manner as SAE
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor in the same time frame as SAEs to 
meet certain local requirements. Therefore, these e vents are considered serious by  [CONTACT_19510].
•Is a cancer (that is not a condition of the study )
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  87
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
•It is not accept able for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may  be instances when copi[INVESTIGATOR_63475] b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms , and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of i ntensity /toxicity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes a s 
described in the definition of an SAE, not when it is rated as severe.
Assessment of c ausality
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indica ted or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care profession als.
•New or updated information will be recorded in the CRF.
•The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SA E, and other reportable safety e vent reporting to Sponsor via electronic d ata 
collection t ool
•The primary  mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
•Electronic reporting procedures can be found in the EDC data entry  guidelines (or 
equivalent).
•If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
•Reference Section 8.4.[ADDRESS_1275578]:   MK-7264  88
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
•The site will enter the SAE data into the electr onic sy stem as soon as it becomes 
available.
•After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant o r receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator S tudy File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the inv estigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent) . 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  89
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.4 Appendix 4: Devic e Events, Adverse Device Events, and Medical Device 
Incidents: Definition s, Collection, and Documentation
Not Applicable 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  90
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below):
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study  intervention, addi tional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study  entry .
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high follicle stimulating hormone (FSH) level in the postmenopausal range may  
be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormone replacement therap y (HRT). However, in the absence 
of [ADDRESS_1275579]:   MK-7264  91
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.5.2 Contraception Requirements
Female Participants
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User D ependency
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only contraceptive implantb,c
•Intrauterine hormone -releasing system (IUS)c,d
•Intrauterine device (IUD)
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly 
effective method of contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia can come from the site personnel’s revie w of the participant’s 
medical records, medical examination, or medical history intervie w.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly.
•Com bined (estrogen -and progestogen -containing) hormonal contraceptionc,d
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptionc,d
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study i ntervention. The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and 
usual lifestyle of the participant.
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
•Progesterone -only hormonal contraception where inhibition of ovulation is not the primary mode of 
action
•Male or female condom with or without spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double 
barrier methods)e 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  92
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275580] -use failure rates (ie, when used consistently and 
correctly).
c.If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, 
acceptable contraceptive implants are limited to those which inhibit ovulation
d.IUS is a progestin -releasing IUD.
e.A combination of male condom with either cap, diaphragm, or sponge with spermicide are considered 
acceptable, but not highly effective, birth control methods.
Note: The follow ing are not acceptable methods of contraception:
-Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdraw al (coitus interruptus), 
spermicides only, and lactational amenorrhea method (LAM).
-Male and female condom should not be used together (due to risk of fail ure with friction).
10.5.[ADDRESS_1275581]:   MK-7264  93
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
Biomedical Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition .1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deox yribonucleic acid.
e.RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected i n this study  as outlined in Section 8. 11will be 
used in various experiments to understand:
◦The biology  of how drugs/vaccines work
◦Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
◦Other pathway s drugs/vaccines may  interact wi th
◦The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used b y the Sponsor or those working for or 
with the Sponsor.
3. Summary of Procedures for Future Biomedical Research.
a.Participants for Enrollment 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  94
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
All participants enrolled in the clinical study will be considered for enrollment in the 
future biomedical research substudy
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study  visit by  [CONTACT_63559] d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delay ed, present consent at next possible Participant Visit. Consent forms 
signed b y the participant will be kept at the clinical study  site under secure storage for 
regulatory  reasons.
A template of each stud y site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical r esearch will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroy ed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usually  be obtained at a time when the participant is 
having blood drawn for other study  purposes.
4.Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact lit tle or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history  and intervention outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing information embedded within it . The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  95
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275582] party  (eg, a university  investigator) designated by 
[CONTACT_1034]. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in this substudy . Future biomedical r esearch 
specimens remaining with the third part y after specific analysis is performed will be 
reported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may  withdraw their consent for future biomedical research and ask that their 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contact[CONTACT_491494]. If medical records 
for the main study  are still available, the investigator will contact [CONTACT_111972] ([EMAIL_1250] ). Subsequently , the 
participant's specimens will be flagged in the biorepository and restricted to main study 
use only . If specimens were collected from study participants specifically for future 
biomedical r esearch, these specimens will be removed from t he biorepository  and 
destroy ed. Documentation will be sent to the investigator confirming withdrawal and/or 
destruction, if applicable. I t is the responsibility  of the investigator to inform the 
participant of completion of the withdrawal and/or destructio n, if applicable. Any  
analyses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b y the Sponsor will continue to be used as 
part of the overall research study  data and results. No new ana lyses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study 
records) or the speci mens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_1275583]:   MK-7264  96
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275584] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Dat abase user authentication is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No informati on obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_908499]. Participants will not be 
identified by  [CONTACT_63561].
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the fu ture biomedical r esearch informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidential ity. In this highl y unlikely  situation, there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly  to 
[EMAIL_1250] . 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  97
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Conference on Harmonization [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/definitions-
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Avail able at http://i- pwg.org/ 
4.Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/ 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  98
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.7 Appendix 7: Country -specific Requirements
Not Applicable 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  99
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.8 Appendix 8: Blood Volume Table
Pre-study Treat ment Periods Post-studyTotal 
CollectionsmL Per 
CollectionTotal 
mL/ Test
Laboratory Safety Tests
(Chemistry, Hematology, 
Urinalysis)1 4 1 6 12.5 75
HIV/Hepatitis Screen (at 
the discretion of the 
investigator)1 1 3.5 3.5
Blood for Planned Genetic 
Analysis1 8.5 8.5
Blood (Plasma and Serum) 
for Clinical Biomarkers4 4 20 80
Blood for MK -7264 6 6 3 18
Total Blood Volume per Participanta185mL
aIf additional pharmacokinetic/ pharmacodynamic /efficacy and/or safety analysis is necessary, additional blood (up to 
50mL) may be obtained.  
  056LPF 
  05FQVP
PRODUCT:   MK-7264  100
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.9 Appendix 9: 12-Lead Electrocardiogram Abnormality Criteria
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure Criteria Potentially Significant 
Post-randomization Findings 
(clarification on action to take)
RHYTHM
Sinus Tachycardia 110 bpmHR >110 bpm and HR increase of 
≥25bpm from baseline
Sinus Bradycardia <40 bpmHR <40 bpm and HR decrease of 
≥5bpm from baseline
Sinus Pause/Arrest >2.0 seconds >2.0 seconds
Atrial Premature C omplex 1 beat 3 beats
Ventricular Prema ture C omplex All 3 beats
Ectopic Atrial Rhythm None None
Junctional RhythmJunctional Rhythm with HR < 40 
bpmJunctional Rhythm with HR < 40 
bpm
Idioventricular Rhythm All All
Atrial Fibrillation (newly 
diagnosed and untreated)All All
Atrial Flutter All All
Supraventricular Tachycardia All All
Ventricular Tachycardia All All
AXIS
Left Axis DeviationRBBB W ith Left Anterior 
Hem iblock (LAHB)New  Onset LAHB
Right Axis DeviationRBBB W ith Left Posterior 
Hem iblock (LPHB)New  Onset LPHB
CONDUCTION
1st Degree A V Block PR  230 msPR  230 ms   + Increase of 15 ms; 
or PR Increase of > 25%
2nd Degree AV Block Mobitz Type II Mobitz Type II
3rd Degree A V Block All All
LBBB All All
RBBBRBBB With LAHB/LPHB as 
Defined A boveNew  Onset RBBB (N ot Including 
Rate-related)
Incomplete Right BBB 
(ICRBBB) (QRS <120 ms)No E xclusion Nothing
Short PR/ Preexcitation 
SyndromeDelta W ave + PR <[ADDRESS_1275585] + PR <120 ms
Other Intra -Ventricular 
Conduction DelayQRS 130 ms QRS 130 ms + I ncrease of 10 ms
QTc (F)
Male QTc 470 msQTc 500 ms or I ncrease of 60 ms 
From  Baseline
Female QTc 480 msQTc 500 ms or I ncrease of [ADDRESS_1275586]:   MK-7264  101
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1275587]-randomization Findings 
(clarification on action to take)
HYPERTROPHY
Atrial Abnorm alitiesDefinite Evidence of P Mitrale or 
P Pulmo naleDefinite Evidence of P Mitrale or P 
Pulmonale
Ventricular A bnorm alitiesVoltage Criteria for LVH P lus 
Strain PatternVoltage Criteria  for LVH P lus 
Strain Pattern
MYOCARDIAL INFARCTION
Acute or Recent All All
Old All All
ST/T MORPHOLOGY
ST Elevation S uggestive of 
Myocardial Injury In [ADDRESS_1275588] -T Changes 
(In 2 or More L eads)No exclusion In 2 or more contiguous lea ds
PACEMAKER All All
Baseline is defined as Predose Day -1; ms=milliseconds, mm=millimeter 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  102
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory  values obtained at prestud y (screening) visit and/or predose evaluation:
A.If all protocol- specified laboratory  values are normal, the participant may  enter the stud y.
B.If a protocol specified laboratory  value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the p articipant will be 
excluded from the study .
C.If ≥1 protocol -specified laboratory  value not specified in the inclusion/exclusion criteria 
is outside the normal range, the following choices are available:
i. The participant may  be excluded from the study ;
ii. Theparticipant may  be included in the study  if the abnormal value(s) is not 
clinically  significant (NCS) (the investigator must annotate the laboratory  
value “NCS” on the laboratory  safet y test source document).
iii. The participant may  be included in the study  if the abnormalit y is consistent 
with a pre -existing medical condition which is not excluded per protocol (eg, 
elevated eosinophil count in a participant with asthma or seasonal allergies),
the medical condition should be annotated on the laboratory report .
OR
iv. The abnormal test may  be repeated (refer items a. and b. below for 
continuation of algorithm for repeated values).
If the repeat test value is within the normal range, the participant may enter the study.
If the repeat test value is still abnormal, the study  investigator will evaluate the potential 
participant with a complete history  and ph ysical examination, looking especially  for 
diseases that could result in the abnormal laboratory value in question. If such diseases 
can be ruled out, and if the abno rmal laboratory  value is not clinically  relevant, then the 
participant may  enter the study .
D.If there is an y clinical uncertaint y regarding the significance of an abnormal value, the 
participant will be excluded from the stud y. 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  103
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
10.11 Appendix 11: Abbreviations
Abbreviation Expanded Term
ADL activities of daily living  
AHI Apnea-Hypopnea Index
AE adverse event 
BDS blood drug screen
CAC Clinical Adjudication Committee
CNS central nervous system 
CRF Case Report Form 
CRU clinical research unit
C-SSRS Columbia -Suicide Severity Rating Scale 
eCTA exploratory Clinical Trial Application
CTCAE Common Terminology Criteria for Adverse Events
CTFG Clinical Trial Facilitation Group 
DILI drug-induced liver injury
DMC Data Monitoring Committee 
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic Case Report Form
EDC electronic data collection 
EEG electroencephalogram
EMA European Medicines Agency
EMG electromyograph y
EOC Executive Oversight Committee 
EOG electrooculography
FDAAA Food and Drug Administration Amendments Act
FSH Follicle stimulating hormone 
GCP Good Clinical Practice 
HRT hormone replacement therapy
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IND Investigational New Drug 
IRB Institutional Review Board 
IUD intrauterine device
IUS intrauterine hormone -releasing system
MTD maximum tolerated dose 
NDA New  Drug Application 
NOAEL no observed adverse effect level 
OSA Obstructive sleep apnea
PET positron emission tomography 
PK pharmacokinetic
PSG Polysomnography 
QP2 department of quantitative pharmacology and pharmacometrics
RNA ribonucleic acid
SAC Scientific Advisory Committee
SAE serious adverse event 
siDMC Standing Internal Data Monitoring Committee
SoA schedule of activities 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  104
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
Abbreviation Expanded Term
S[LOCATION_003]R suspected unexpected serious adverse reaction
UDS urine drug screen
WOCBP woman/ women of childbearing potential  
  056LPF 
  05FQVP
PRODUCT:   MK-7264  105
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
11 REFERENCES
[Peppard, P. E., et al 
2013]Peppard PE, Young T, Barnet JH, Palta M, Hagen 
EW, Hla KM. I ncreased prevalence of sleep -
disordered breathing in adults. Am J Epi[INVESTIGATOR_5541]. 
2013;177(9):1006 -14.05349B
[Young, T., et al 2009] Young T, Palta M, Dempsey  J, Peppard PE, Nieto 
FJ, Hla KM. Burden of sleep apnea: rationale, 
design, and major findings of the Wisconsin sleep 
cohort study . WMJ. 2009;108(5):246 -9.0534BR
[Pagel, J. F. 2007] Pagel JF. Obstructive s leep apnea (OSA) in 
primary  care: evidence -based practice. J Am 
Board Fam Med. 2007 Jul -Aug;20(4):392 -8.0534BQ
[Hale, C. S. 2005] Hale CS. Obstructive sleep apnea and 
cardiovascular disease and mortality : the argument 
for causality . J Insur Med. 2005;37: 272-82.0536BM
[Parish, J. M., et al 
2007]Parish JM, Adam T, Facchiano L . Relationship of 
metabolic sy ndrome and obstructive sleep apnea. J 
Clin Sleep Med. 2007;3(5):467- 72.0534TC
[Weaver, T. E., et al 
1997]Weaver TE, Kribbs NB, Pack AI, Kline LR, 
Chugh DK, Maislin G, et al. Sleep -disordered 
breathing: night- to-night variability  in CPAP use 
over the first three months of treatment. Sleep. 
1997;20(4):278- 83.0536BZ
[Means, M. K., et al 
2004]Means MK, Edinger JD, Husain AM. CPAP 
compliance in sleep apnea patients with and 
without laboratory  CPAP titration. Sleep Breath. 
2004;8(1):7- 14.0534TD
[Rotenberg, B. W., et al 
2016]Rotenberg BW, Murariu D, Pang KP. Trends in 
CPAP adherence over twenty  years of data 
collection: a flattened curve. J Otolary ngol Head 
Neck Surg. 2016;45:43.0534TF
[Dempsey , J. A., et al 
2014]Dempsey  JA, Xie A, Patz DS, Wang D. 
Physiology  in medicine: obstructive sleep apnea 
pathogenesis and treatment -considerations 
beyond airway  anatom y. J Appl Phy siol. 
2014;116:3- 12.05349C 
  056LPF 
  05FQVP
PRODUCT:   MK-7264  106
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
[Sands, S. A., et al 
2018]Sands SA, Edwards BA, Terrill PI , Butler JP, 
Owens RL, Taranto- Montemurro L, et al. 
Identify ing obstructive sleep apnoea patients 
responsive to supplemental ox ygen therap y. Eur 
Respir J. 2018;52:1800674.0536XW
[Younes, M. 2014] Younes M. CrossTalk proposal: elevated loop gain 
is a consequence of obstructive sleep apnoea. J 
Physiol. 2014;592(14):2899 -901.05354L
[Paton, J. F. R., et al 
2013]Paton JFR, Ratcliffe L , Hering D, Wolf J, Sobotka 
PA, Narkiewicz K. Revelations about carotid bod y 
function through its pathological role in resistant 
hypertension. Curr Hy pertens Rep. 2013;15:273 -
80.05354M
[Edwards, B. A., et al 
2012]Edwards BA, Sands SA, Eckert DJ, White DP, 
Butler JP, Owens RL , et al. Acetazolamide 
improves loop ga in but not the other phy siological 
traits causing obstructive sleep apnoea. J Phy siol. 
2012;590(5):1199 -211.05354N
[Nussbaumer -Ochsner, 
Y., et al 2012]Nussbaumer -Ochsner Y, Latshang TD, Ulrich S, 
Kohler M, Thurnheer R, Bloch KE. Patients with 
obstructive sleep apnea syndrome benefit from 
acetazolamide during an altitude sojourn: a 
randomized, placebo- controlled, double -blind trial. 
Chest. 2012 Jan;141(1):131 -8.0536XV
[North, R. A. 2004] North RA. P2X3 receptors and peripheral pain 
mechanisms. J Phy siol. 2004 Jan 15;554(Pt 
2):301- 8.04JRR8
[Tay lor, K. S., et al 
2018]Taylor KS, Millar PJ, Murai H, Haruki N, 
Kimmerly DS, Bradley  TD, et al. Cortical 
autonomic network grey  matter and s ympathetic 
nerve activity  in obstructive sleep apnea. Sleep. In 
press 2018.0536BS
[Edwards, B. A., et al 
2014]Edwards BA, Sands SA, Owens RL, White DP, 
Genta PR, Butler JP, et al. Effec ts of h yperoxia 
and hy poxia on the phy siological traits responsible 
for obstructive sleep apnoea. J Phy siol. 
2014;592(20):[ADDRESS_1275589]:   MK-7264  107
PROTOCOL/AMENDMENT N O.:  039 -02  
MK-7264 -039-02 FI NAL PROTOCOL 02-APR -2019
[Nakay ama, H., et al 
2003]Nakay ama H, Smith CA, Rodman JR, Skatrud JB, 
Dempsey  JA. Carotid body  denervation eliminat es 
apnea in response to transient hy pocapnia. J Appl 
Physiol. 2003 Jan;94:155 -64.0536XH
[Pi[INVESTIGATOR_908485], W., et al 
2016]Pi[INVESTIGATOR_908485] W, Moraes DJ, Ratcliffe LE, Nightingale 
AK, Hart EC, da Silva MP, et al. Purinergic 
receptors in the carotid body  as a new drug targ et 
for controlling h ypertension. Nat Med. [ADDRESS_1275590];22(10):1151- 1159.04JRWQ
[Bairam, A., et al 2013] Bairam A, Lumbroso D, Joseph V. Effect of 
progesterone on respi[INVESTIGATOR_908500]. 
Respir Phy siol Neurobiol. 2013;185:515 -25.0536XJ
[Katay ama, P. L ., et al 
2017]Katay ama PL, Charles I, Pi[INVESTIGATOR_908485] W, Abdala AP, 
Salgado HC, Ford AP, et al. P2X3 receptor 
antagonism reduces the occurrence of apnoeas in 
newborn rats [abstract]. FASEB J. 2017 Apr;31([ADDRESS_1275591] ). Abstract no. lb829.053BPB
[Narkiewicz, K., et al 
2016]Narkiewicz K, Ratcliffe LEK, Hart EC, Briant 
LJB, Chrostowska M, Wolf J, et al. Unilateral 
carotid bod y resection in resistant hypertension: a 
safet y and feasibility trial. JACC Basic Transl Sci. 
2016 Aug;1(5):313 -24.0536XK
[Sands, S. A., et al 
2018]Sands SA, Edwards BA, Terrill PI , Taranto -
Montemurro L, Azarbarzin A, Marques M, et al. 
Phenoty pi[INVESTIGATOR_908501] y in patients with obstructive 
sleep apnea. Am J Respir Crit Care Med. 2018 
May 1;197(9):1187 -97.0536XT
[Wellman, A., et al 
2008]Wellman A, Malhotra A, Jordan AS, Stevenson 
KE, Gautam S, White DP. Effect of ox ygen in 
obstructive sleep apnea: role of loop gain. Respir 
Physiol Neurobiol. 2008;162:144 -51.05349D 
  056LPF 
  05FQVP